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1. PHYSIOLOGIC DEFENSE MECHANISMS IN PERITONITIS
Intra-abdominal  sepsis is a life threatening condition caused by perforation of the digestive tract, in
the majority of cases. Contamination of the abdominal cavity with microorganisms will activate a
chain of defense mechanisms to control infection. Bacteria that contaminate the peritoneal cavity are
transported to the subdiaphragmatic spaces by the cephalad directed fluid stream in the peritoneal
cavity. Via stomata in the mesothelial layer that covers the diaphragm, fluid and (bacterial) particles
drain into the lymphatic lacunae of the diaphragm. The lymph is actively transported by the 
diaphragmatic muscle pump into the thoracic duct that drains into the subclavian vein(1-3). The 
microorganisms that enter the circulation evoke a systemic response and are eliminated by the 
immune defenses of the host(4). 
Contamination of the abdominal cavity will elicit a local immune response. Upon contact with 
microorganisms, the mesothelium cells express a cascade of cytokines, chemokines and adhesion
molecules, resulting in recruitment of polymorph nuclear neutrophils (PMNs) and macrophages to
the peritoneal cavity. This process is partly mediated by peritoneal macrophages(5;6). The release of
these cytokines and chemokines leads to mast cell activation, which in turn will release vasoactive
mediators(7). These mediators increase vascular permeability, which is a general step in any inflam-
matory response and is aimed at carrying fluid, proteins and cells to the focus of infection. As a 
result a fibrin-rich exudate is formed containing cytokines and chemokines, which modulate the 
inflammatory response(8). In addition, the peritoneal exudate enhances opsonization(7;9;10). 
In response to infection of the abdominal cavity, both coagulation and fibrinolysis are upregulated.
In the early phase coagulation predominates, leading to the formation of fibrinous adhesions. Fibrin
is of importance in preventing bacterial spread thereby reducing the systemic inflammatory 
response. In addition, bacteria can be trapped in fibrin clots, leading to containment of the infectious
focus(11;12). 
Normally, during the course of peritonitis, fibrin is gradually degraded by plasminogen activators
(PAs). Tissue type plasminogen activator (t-PA) is the most important PA in peritonitis. T-PA is produced
in the abdominal cavity(13), with mesothelium cells being the most important source(14;15;16). 
During resolution of inflammation, fibrinolytic activity will be upregulated. Upon fibrin degradation
bacteria will gradually be released into the abdominal cavity and eliminated by the local immuno-
logical defenses.
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Different factors have been identified that interfere with physiologic resolution of peritonitis.
1. The fibrinous adhesions that are involved in compartmentalization of infection can impair the 
circulation of abdominal fluid. In addition, fibrin may occlude the diaphragmatic stomata(17;18) 
thereby hampering the physiologic clearance of bacteria from the abdominal cavity. This will 
promote intra-abdominal  abcess formation and adhesion formation; the former being a well-known
source of ongoing or recurrent abdominal infection.
2. Bacterial synergy is  known to adversely  influence the outcome of peritonitis(19). Synergy is a 
complex phenomenon probably occurring on the basis of reduced peritoneal clearance as well as
by bacteria providing reciprocal growth factors(20). In addition it has been reported that some 
microorganisms, for instance Enterococcus faecalis, not only contribute to bacterial synergy, but also
may have a direct inhibitory effect on phagocytosis and intracellular killing(21).
3. Adjuvant substances such as blood or enteric juices adversely influence the local defenses. Bile 
for instance is associated with reduced peritoneal absorption and impaired local defense(22). 
Hemoglobin interferes with chemotaxis, phagocytosis, and phagocytic killing(23).
4. Like most pathogens, intraperitoneal bacteria adhere to peritoneal mesothelial cells and invade
the submesothelial tissues(24).
If the local defense mechanisms in the peritoneal cavity fail, the inflammatory process in the 
abdominal cavity may become self-perpetuating which ultimately leads to the development of  multi
organ failure and death(25;26).
2. FIBRIN: FORMATION AND DEGRADATION
Fibrin
Fibrin is an insoluble, endogenous polymer, formed as the result of conversion of soluble fibrinogen by
thrombin(14;27). Fibrinogen is a protein of 340,000 Dalton(28) mainly synthesized in the liver. The
serum concentration varies with a half life-time in the circulation of approximately 3 days. Fibrinogen
is a dimer, which consists of three peptide chains abbreviated with alpha, beta, and gamma(29). 
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Fibrin formation
The formation of fibrin is a well studied part of the intravascular coagulation cascade. The intra-
abdominal  coagulatory system has not been described in detail but probably occurs similar to 
intravascular clot formation (see figure 1). Classically, an intrinsic and an extrinsic pathway are described
but in recent literature this discrimination is omitted since coagulation is supposed to be exclusively
generated by Tissue Factor (TF). Thrombin formation at extravascular sites is initiated by expression of
cell-anchored TF and propagated through assembly of the prothrombinase complex (30), via activation
of factor VII, X and V, respectively. The prothrombinase complex catalyses the conversion of prothrombin
into thrombin. Thrombin in turn is responsible for conversion of plasma fibrinogen into fibrin. The 
TF- factor Va complex can also activate factor IX, forming a tenase complex with activated factor IX and
X, generating additional factor Xa, which amplifies coagulation. This is markedly facilitated in the 
presence of a phospholipids surface. Probably this surface ideally presented by platelets, is (partly) 
lacking in the abdominal cavity. 
Tissue factor is present in plasma as are all other necessary clotting factors (31), but in peritonitis TF is
expressed by mesothelial cells (30) and local inflammatory cells such as neutrophils and monocytes
(32). The expression of TF is modulated by several inflammatory mediators and lipopolysaccharide (32;33).
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Figure 1. Simplified presentation of the intra-abdominal clotting cascade.
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Figure 1. The formation of fibrin.
(By Douglas M. Tollefsen, Washington University, dept. of Hematology, with permission)
Figure 3. Fibrin degradation.
Cytokines and other inflammatory mediators are expressed when bacteria adhere to mesothelial
cells. The inflammatory mediators induce mast cell degranulation and recruite inflammatory cells
such as macrophages and polymorphonuclear neutrophils (PMNs) (34-37). In addition, vascular per-
meability increases in order to carry fluid, proteins and cells to the site of damage(7). Subsequently,
a fibrinogen-rich exudate, that also contains clotting factors, is formed: the first step in fibrin 
formation in peritonitis(9;10;38). 
Next, the dimeric fibrinogen molecule is cleaved by thrombin to produce soluble fibrin monomers,
fibrinopeptide A and fibrinopeptide B. Fibrinopeptide A is frequently used as an early marker of 
fibrinogen-to-fibrin conversion(39). The plasma-borne enzyme thrombin not only contributes 
directly to coagulation by catalysing the formation of fibrin, but also orchestrates cellular effects
such as platelet activation and vasodilatation(40). 
Finally, enhanced by the thrombin-activated plasma factor XIIIa, the fibrin monomers are then cross-
linked in the longitudinal as well as in transverse direction (Figure 2). After polymerization, a sticky
fibrin network is formed,  which explains the tendency of damaged or inflamed peritoneal surfaces
to adhere to each other(27). As vascular patency will be restored after thrombus lysis, release of the
attachment of adhesive peritoneal structures is achieved by lysis of the fibrin deposits(41). However,
if the process of fibrin formation is unopposed by physiologic fibrinolysis, the fibrin mesh will 
become infiltrated by fibrocollagenous tissue thus forming fibrous adhesions(42).
Fibrin degradation
Under physiologic circumstances fibrin is degraded by an enzymatic system. This fibrinolytic system
comprises a pro-enzyme plasminogen, which is converted into its active form, plasmin, by plasmi-
nogen activators (PAs). Plasmin in turn catalyzes the breakdown of fibrin into fibrinogen degradation
products (Figure 3). 
Two PAs have been identified: tissue type plasminogen activator (t-PA) and urokinase type plasmi-
nogen activator (u-PA). Both PAs are equally effective in lysing fibrin clots, but t-PA is much more 
fibrin specific and therefore less likely to act on systemic fibrinolysis (14;43); it has been detected in
several types of tissue (44-46). In secondary peritonitis t-PA is  produced in the abdominal cavity (13),
with mesothelium cells being the most predominant source of t-PA production (14;15;15;16;47). Human
peritoneal mesothelial cells (HMCs) play a critical role in maintaining the intraperitoneal balance 
between fibrinolysis and coagulation by expressing the fibrinolytic enzyme tissue-type plasminogen
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14 chapter 1
activator (t-PA) as well as a specific plasminogen activator inhibitor, PAI-1, and the procoagulant 
protein tissue factor (TF) (47;48). 
Altogether, fibrin is an important component of the fibrinolytic/coagulatory system in the inflam-
matory response in the peritoneal cavity. The wall of any abscess consists mainly of fibrin.  Abscess
formation on one hand leads to entrapment of bacteria, resulting in containment of infection, 
thereby  reducing systemic spread of bacteria (49-51). On the other hand, bacteria embedded in an
abscess are shielded from antibiotic therapy and from immunologic defense mechanisms (52-54).
3. AIM OF THIS DISSERTATION
This thesis reports the results of a series of experiments on the subject of reducing intra-abdominal
abscess formation by intraperitoneal application of recombinant tissue type plasminogen activator.
The following issues are addressed:
1. The development of a model, which allows for the study of mechanisms involved in the prevention
of intra-abdominal  abscess formation in generalized peritonitis. 
2. To determine whether optimal abscess prevention can be achieved by changing the method of 
administration and to optimize the dosage scheme of intraperitoneally applied rtPA.
3. To investigate if both rtPA and urokinase can be used intraperitoneally to reduce abscess formation
without inducing adverse side-effects.
4. To determine if  prolonged intraperitoneal rtPA treatment is more effective than treatment during
24 hours and whether delayed rtPA treatment is still effective in reducing abscess formation.
5. To study the effects of systemic antibiotics on intra-abdominal  abscess formation and survival,
both in the absence and presence of intraperitoneally applied rtPA.
6. To study whether intraperitoneal application of rtPA impairs healing of bowel anastomoses and 
abdominal wall fascia after surgical debridement of secondary peritonitis in the rat.
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ABSTRACT
Background
Intra-abdominal abscesses are a potential source of recurrent or residual infection after surgical 
intervention for secondary peritonitis. The development of therapies requires a model which combines
low mortality with the formation of persisting abscesses and which is also suitable to study the local
inflammatory response.
Methods: 
Wistar rats were injected intraperitoneally with sterile rat feces, increasing doses of E. coli (104-108
cfu/ml) and a fixed dose of B. Fragilis (104 cfu/ml). After one h a laparotomy was performed and the
peritoneal cavity was debrided. Blood samples were taken after 6 and 24 h. Abdominal fluid samples
were collected after 24 and 72 h. The rats were killed after 5 days and the abdomen was inspected for
abscesses.
Results: 
Mortality was 90% in the two groups with the highest doses of E. coli and 30% in those with the
two lowest doses. In the latter groups all surviving rats but one showed intra-abdominal abscesses
and bacteremia was encountered frequently, especially after 24 h in the 105 cfu E. coli group. 
The groups receiving 104 - 106 cfu E.coli showed similar plasma IL-6 concentrations after 6 h which 
lowered significantly after 24 h. No circulating TNF-α was found. Considerable concentrations of 
TNF-α, IL-6, IL-1β and IL-10 were found in the peritoneal fluid after 24 h. At 72 h cytokine levels were
reduced significantly and remained the highest in the animals dosed with 106 cfu E. coli.
Conclusions: 
The present model is suitable to study the mechanisms involved in, and prevention of, intra-abdo-
minal abscess formation after surgical treatment of generalized peritonitis.
a peritonitis model with low mortality and persisting intra-abdominal abscesses 21
INTRODUCTION
Generalized peritonitis is a life threatening disease caused, in the majority of cases, by perforation of
the digestive tract. Sometimes, this disease can be controlled by local defense mechanisms: formation of
fibrinous adhesions, clearance of bacteria via lymphatic stomata in the diaphragm and the cellular de-
fenses of the peritoneal cavity(1;2). However, if these mechanisms fail, the peritoneal cavity is flooded
with bacteria, inflammatory mediators and visceral contents. It will turn into one large inflamed
compartment in which the local defense mechanisms may become detrimental to the patient. 
Fibrin deposition on the diaphragm may prevent the clearance of bacteria from the abdominal 
cavity by occluding the lymphatic stomata, thereby containing the infection.  However, entrapment
in fibrin clots renders bacteria unreachable for phagocytes and antibiotic therapy(3-5). Shortage of
oxygen in the peritoneal fluid and neutrophil activation by complement, bacteria trapped in fibrin and
visceral contents, will cause extracellular release of lysozymal enzymes. These are capable of digesting
normal and viable tissue resulting not only in necrosis but also in continued stimulation of inflam-
mation and influx of neutrophils(6). This entire process may readily become self-perpetuating, even
in the absence of bacteria(2;7;8). The outcome will be fatal without surgical intervention(9). 
Removal of the source of contamination, debridement of the abdominal cavity, proper antibiotics and
drainage of abscesses are the cornerstones of successful surgical therapy in generalized peritonitis.
However, in a considerable number of cases adequate therapy still results in the formation of residual
abscesses, which carry a substantial mortality and morbidity (2). Recently, a mortality rate of 30%
was reported in ICU patients with ongoing intra-abdominal infection; it can be as high as 50% if 
recurrent infection occurs(10). 
The search for further treatment options is best performed in an experimental model, which repro-
ducibly combines a low mortality with the formation of persisting, preferably multiple, abscesses
with time. In addition, multiple measurements of local inflammatory mediators would contribute
to our understanding of the pathophysiology. An intraperitoneal bolus challenge with Escherichia
coli (E. coli) and Bacteroides fragilis (B. fragilis) is believed to initiate events which are a valid repre-
sentation of the course of secondary peritonitis(11). To our knowledge, models described in the 
literature have not yet incorporated all of the requirements mentioned above. The aim of the present
study was to develop such a model, which allows for the the study of mechanism involved in, and 
prevention of, intra-abdominal  abscess formation after surgical treatment of generalized peritonitis. 
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MATERIALS AND METHODS
Animals
Male Wistar rats weighing 250-280 g, (Harlan BV, Horst, the Netherlands) were housed two per cage
and accustomed to laboratory conditions for 1 week before the start of the experiment. All animals
were weighed daily and had free access to water and standard rodent chow throughout the entire
experimental period (Hope Farms, Woerden, the Netherlands). The Animal Ethics Review Committee
of the Radboud University Nijmegen, approved the study.
Fecal suspension
Fresh feces from Wistar rats were collected and suspended in twice the volume of sterile,  pyrogen-
free water.  The suspension was sterilized in an autoclave. After centrifugation (15 min at 750 x g),
the  upper two layers were combined, autoclaved again  and stored at 40C. At the day of the experi-
ment 1 ml of fecal suspension was mixed with 0.5 ml of Schaedler solution containing either 104, 105,
106, 107 or 108 cfu E. coli, strain 25922 from the American Type Culture Collection. Immediately before
inoculation 0.5 ml of Schaedler solution containing 104 cfu from a clinical B. fragilis isolate was added
to the fecal inoculum as well. Bacterial concentrations were determined by densitometry and 
nephelometry (BD; Crystalspec, Franklin Lakes, NJ, USA) at the day of inoculation.
Experimental design
Sixty animals were randomly divided into six groups of ten rats. Peritonitis was induced in five groups
of rats by percutaneous intra-abdominal  injection in the right lower quadrant of 2 ml of a fecal 
suspension containing 104 cfu B. fragilis and 104, 105, 106, 107 or 108 cfu E. coli, respectively. The control
group was injected with  sterilized faeces only.
One h after inoculation, the rats were anesthetized by inhalation of a mixture of isoflurane-oxygen-
nitrous oxide. The abdominal cavity was debrided and rinsed with 5 ml of sterile saline of 380C. 
During debridement (partial) omentectomy was performed in order to remove macroscopic omental
contamination. The abdomen was closed with a running suture of 4.0 Polyglactin 910 (Vicryl®, 
Ethicon,  Amersfoort, The Netherlands), the skin was closed with staples.  Rats received 5 ml normal
saline subcutaneously for resuscitation. 
Blood samples were taken at 6 and 24 h after inoculation by cardiac puncture. Peritoneal fluid 
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samples were taken after 24 and 72 h via a laparotomy. After 5 days the animals were killed by CO2
asphyxiation. The abdomen was inspected, by the same persons who were unaware of the treat-
ment, with particular attention to the number and location of abscesses.
Sample collection
After inducing anaesthesia with an isoflurane-oxygen-nitrous oxide mixture, 1 ml blood samples
were taken by cardiac puncture and collected in tubes containing 50 IU heparin. Part was used for bac-
terial culturing and the remainder was centrifuged for 10 min at 1600 x g.  The plasma was stored at
-800C for cytokine assays (see below). Peritoneal fluid samples were also collected under anaesthesia:
After reopening the abdomen, 5 ml of sterile saline of 380C was installed in the abdominal cavity. 
The abdomen was gently massaged and at least 2 ml of fluid were withdrawn. The samples were
centrifuged for 10 min at 750 x g and supernatants stored at -800C until further analysis.
Sample analysis
Heparinized blood samples (300 µl) were cultured for the presence of E. coli. Serial dilutions in Brain
Heart Infusion broth were plated onto MacConkey blood agar plates. After 24 and 48 h of incubation
at 370C bacteria were counted and identified. 
Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured in plasma as well as in 
peritoneal fluid. In addition to these cytokines, interleukin-1β (IL-1β) and interleukin-10 (IL-10) were
measured in peritoneal fluid. All assays were performed using commercially available ELISA kits 
(Endogen®, Pierce Biotechnology Inc, Rockford IL, USA). According to the manufacturer, the sensitivities
for the various assays were < 10 pg/ml for TNF-α, < 12 pg/ml for IL-1β, < 16 pg/ml for IL-6 and < 3 pg/ml
for IL-10, respectively. Cells were counted in peritoneal fluid, after dilution of the sediment with 
saline (to a concentration of 50.000 cells/ml) and staining with May-Grunwald Giemsa reagent.
Statistics
Statistical analysis was performed using Tukey Kramer multiple group comparisons. Kruskal-Wallis
and Mann-Whitney test were applied to process nonparametric data. Survival rates were compared
by Kaplan Meier Survival analysis. P values of < 0.05 are considered significant. 
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RESULTS
Survival
All rats in the control group survived the experimental period. In the rats that received E. coli and B.
fragilis, survival was significantly lower than in the control group and steadily decreased with the
bacterial load (Figure 1). Survival was 70% in groups receiving 104 or 105 cfu E. coli, 40% in the group
with 106 cfu E. coli and 10% after receiving either 107 or 108 cfu E. coli, respectively.
Clinical course
All rats became severely ill after inoculation, as was evident from lack of movement, erect body hair
and anorexia. Body weight decreased significantly within 24 h after inoculation and stabilized 
thereafter. Weight course was similar in the control group and the groups which had received 104 -
106 cfu E. coli (Figure 2).
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Figure 1. Survival.
Survival in six groups of rats inoculated on day 0 with sterile faeces (con-
trols) or sterile faeces mixed with a fixed dose of B. fragilis and increasing
doses of E. coli.    : controls;    : 104 cfu E. coli;    : 105 cfu E. coli;    : 106 cfu E.
coli; 107 cfu E. coli;    : 108 cfu E. coli.
Figure 2. Course of body weight.
Daily body weight in four groups of rats inoculated on day 0 with sterile 
faeces (controls) or sterile faeces mixed with a fixed dose of B. fragilis
and increasing doses of E. coli. Average weight is expressed as percen-
tage of the weight at inoculation.    : controls;    : 104 cfu E. coli;  : 105 cfu
E. coli;    : 106 cfu E. coli. The results of the groups receiving 107 or 108 cfu
E. coli are not shown since only 1 rat survived in each group.
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Abscess formation
None of the rats in the control group, inoculated with sterile faeces only, developed abscesses. 
Fifteen out of 18 survivors in the peritonitis groups inoculated with 104 - 106 cfu E. coli showed intra-
abdominal  abscesses after 5 days (Table 1). The median number of abscesses per animal did not 
differ significantly between these groups: 2, 2.5 and 1.5 after 104, 105 or 106 cfu E. coli, respectively.
Blood cultures
Blood cultures from the control group were never positive for E. coli. Six h after inoculation, when all
rats were still alive, cultures were already positive in a majority of rats in the groups which had 
received 106 cfu E. coli or more (Table 2). Median concentrations were 0 cfu/ml in the groups receiving
104 or 105 cfu E. coli and 50, 2050 and 5300 cfu/ml after inoculation with 106, 107 or 108 cfu E. coli, res-
pectively. After 24 h, frequency of positive blood cultures increased. Median concentrations increased
from 0 to 1200 cfu/ml in the 105 cfu E. coli group and from 50 to 1700 cfu/ml in the group which had
received 106 cfu E. coli. 
Table 1. Abscess formation.
Abscesses were counted five days after inoculation. The controls were 
inoculated with sterile faeces only, the experimental groups with sterile
faeces, 104 cfu B. fragilis and increasing doses of E. coli.  * p<0.05 vs controls.
Table 2. Frequency of bacteremia.
The controls were inoculated with sterile faeces only, the experi-
mental groups with  sterile faeces, 104 cfu B. fragilis and increasing
doses of E. coli.
Survivors Number of
with abcesses abcesses/rat
Controls 0/10 (0%)
104 cfu E. coli 7/7 (100%)* 1 - 3
105 cfu E. coli 6/7 (86%)* 1 - 4
106 cfu E. coli 2/4 (50%) 1 - 2
6 h 24 h
Controls 0/10 0/10
104 cfu E. coli 0/10 2/10
105 cfu E. coli 1/10 9/10
106 cfu E. coli 7/10 6/6
107 cfu E. coli 8/10 0/1
108 cfu E. coli 9/10 2/2
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Peritoneal cells and cytokines
Differential cell counts were performed in the abdominal fluid collected from the control group and
the group which had received 106 cfu E. coli. The percentage of neutrophils in the control group went
down from 74 ± 9 (mean ± SD, n=4) at 24 h to 20 ± 12 at 120 h. The same happened in the experi-
mental group: 66 ± 13 to 16 ± 9 %. Over the same period the percentage of eosinophils rose from 5 ±
2 to 55 ± 22 % in the controls and from 9 ± 9 to 39 ± 5 % in the group which had received additional
E. coli. Monocytes were 21 ± 8 % and 23 ± 10 % in the controls and 25 ± 7 vs 43 ± 8 % in the experimental
groups. Absolute numbers of cells did not differ between groups. 
Cytokine concentrations were measured in peritoneal fluid, collected after 24 or 72 h, from rats from
the control group and the groups which had received 104 -106 cfu E. coli.
At 24 h substantial levels of TNF-α were found in all groups and after 72 h concentrations were 
reduced. There were no significant differences between groups (Figure 3A). If all values were taken 
together, the median value (range) was 115 (0-359) pg/ml after 24 h and 0 (0-295) pg/ml after 72 h.
For IL-6, equivalent concentrations were also measured in the four groups at 24 h after inoculation.
Figure 3a en 3b. TNF-α and IL-6 in peritoneal fluid.
TNF-α (A) and IL-6 (B) concentrations in peritoneal fluid collected at 24 and 72 h after inoculation in the control group and the groups receiving 104, 105 or 106
cfu E. coli. Data are depicted as medians with 25-75 percentiles in boxes and 5-95 percentiles represented as vertical lines. *: p < 0.05.
A B
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The rather wide range of the values observed in the groups which had received live bacteria was 
caused in each case by values found in a single animal. The overall median concentration was 464
(range: 282-16444) pg/ml. After 72 h concentrations were significantly lower. Those in the group which
had received 106 cfu E. coli remained significantly (p<0.05) higher than those in the control group
and the group with 104 cfu E. coli (Figure 3B). A rather similar picture was obtained for IL-1β and IL-10 
(Figure 4). There were no significant differences between groups after 24 h: taken together the median
concentrations were 312 (30-6000) pg/ml for IL-1β and 254 (26-1400) pg/ml for IL-10. In all groups, values
decreased significantly between 24 and 72 h. At the latter time point, the group which had received the
highest dose of E. coli again showed the highest concentrations, though not always significantly so.
Plasma cytokines
Plasma samples, collected at 6 and 24 h, were analyzed for both TNF-α and IL-6. TNF-α levels were
below the detection limit  (<10 pg/ml) in all samples. At 6 h, IL-6 was present in plasma of all but one
animal, independent of the group (Figure 5). The overall median concentration was 495 (0-1620)
pg/ml. At this time point, median plasma concentrations in 4 rats from the groups which had recei-
ved 107 or 108 cfu E. coli were 1873 and 2291 pg/ml, respectively. After 24 h, plasma IL-6 was significantly
lower than at 6 h in all groups and tended to be higher in the groups with the higher doses of E. coli. 
DISCUSSION
Inoculation of a mixture of sterilized feces, B. fragilis and E.coli in the abdominal cavity of rats follo-
wed by surgical debridement after 1 h, provides a reproducible model to study residual abscesses
after treatment of generalized peritonitis. 
To study the pathophysiology and treatment modalities of intra-abdominal  abscesses, an experi-
mental model with low mortality and a high rate of abscesses is needed. Mortality in the present
model was closely correlated to the amount of E. coli given. At the lower doses of E. coli (104-105 cfu)
the survival was 70-80% accompanied by 86-100% intra-abdominal  abcesses. With the exception of
the group receiving the lowest dose of E. coli, bacteremia occured almost invariably within the first
24 h after the onset of peritonitis.
The current model also includes the sampling of peritoneal fluid at 24 and 72 h after bacterial ino-
culation, in order to measure local inflammatory mediators. For this purpose additional laparotomies
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Figure 4a en 4b. IL-1β and IL-10 in peritoneal fluid.
IL-1β (A) and IL-10 (B) concentrations in peritoneal fluid collected at 24 and 72 h after inoculation in the control group and the groups receiving 104, 105 or
106 cfu E. coli. Data are depicted as medians with 25-75 percentiles in boxes and 5-95 percentiles represented as vertical lines. *: p < 0.05.
Figure 5. IL-IL-6 in plasma.
IL-6 concentrations in plasma collected at 6 and 24 h after inoculation in
the control group and the groups receiving 104, 105 or 106 cfu E. coli. Data
are depicted as medians with 25-75 percentiles in boxes and 5-95 percentiles
represented as vertical lines. *: p < 0.01
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were performed since this allowed the most reproducible method for extraction of fixed volumes of
fluid from the abdominal cavity. Animals recovered quite quickly and without any complications from
the short periods of anesthesia necessary (also at 6 h in order to sample blood). The course of body
weight indicates that they only lost weight in the first 24 h after inoculation as a result of severe and
immediate illness due to the primary bacterial insult. Still, it should be emphasized that the outcome
of the model is the combined result of all procedures described and that no attempt was made, since
this would have exceeded the purpose of the present study, to investigate the contribution of the 
individual parts. A small pilot study preceding the experiment described here showed that inoculation
with saline only, and perfomance of all subsequent procedures, did not result in any pathology at all
(data not shown). 
So far, the animal models used to study intra-abdominal  abscesses are based on either peritoneal con-
tamination with endogenous bacteria using the cecal ligation and puncture (CLP) model or intrape-
ritoneal application of exogenous bacteria, mostly in combination with adjuvant substances. Both
experimental models are relevant to the formation of residual abscesses in rats with generalized 
peritonitis. 
The CLP model is a well-defined experimental model to induce peritonitis. In rats, the cecum is ligated
and punctured with a needle, causing ischemia of the cecum and leakage of its contents into the 
abdominal cavity. The severity of the peritonitis is determined by the diameter of the needle used. If
CLP is followed by cecal resection 12 or 24 h afterwards, mortality can be limited and persisting ab-
scesses will be found. Mortality rates between 0 and 28 % with - mostly single - residual abscesses
in 83% of rats have been reported(12). The model mimics the clinical situation of postoperative peri-
tonitis very well causing a generalized peritonitis by endogenous flora of the rat. However, cecal
ischemia plays a significant role and will influence the inflammatory response. Therefore, the CLP
model appears to be  more appropriate to study generalized inflammatory responses and sepsis than
the local inflammatory responses(13-15). Moreover, in this CLP model surgical therapy is performed
quite some time after the onset of bacterial contamination of the peritoneum, which is often not the
case, and never the intention, in clinical practice. The above is not meant to suggest that the current
model is without a systemic response: both the -transient - presence of bacteria and IL-6 in the 
circulation prove otherwise.
Instillation of a standardized mixture of bacteria most frequently isolated in secondary peritonitis 
together with fecal material mimics the situation of a secondary generalized peritonitis after 
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perforation of the gut(9). In contrast to CLP, peritonitis is caused by bacteria from clinical isolates,
that do not belong to the endogenous flora of the rats, which may influence the immune response.
While several authors have reported on abscess formation after intra-abdominal  bacterial inoculation,
none of the studies mentioned below have included all requirements for such a model (e.g. multiple
abscesses and measurement of local mediators), as stated in the introduction. Rosman et al. inserted
a rat faecal suspension mixed with 104 cfu E. coli and 104 cfu B. fragilis into the peritoneal cavity of rats,
resulting in abscesses in all animals and a mortality of 30%(16). These numbers are in agreement
with our observations. Rotstein and Kao implanted a human fibrin clot containing 2 x 107 cfu E. coli
and 2 x 108 cfu B. fragilis into the abdominal cavity of rats via a laparotomy. All rats developed a single
abscess accompanied by a mortality of 41%(17).  Wandall et al. implanted a gelatin capsule filled with
a mixture of 2.2 x 106 cfu or less E. coli, B. fragilis, sterile feces and barium sulphate and found a single
abscess in all rats without mortality(18). In our study the mortality in the group with 106 cfu E. coli was
60%. Possibly, the gelatin capsule may provide a slower release of bacteria leading to a more pro-
tracted and less severe course of disease. Their study showed the response to intra-abdominal 
bacterial challenge to be reproducible and dose-dependent with respect to mortality, weight change,
food intake and bacteremia. No effort was made to measure the local inflammatory response. The
rationale for adding barium sulphate, which obviously is absent during secondary peritonitis in 
humans and is known to act as an adjuvant to the inflammatory response, remains unexplained(18).
The local inflammatory response was quantified by measuring levels of the pro-inflammatory 
cytokines TNF-α, IL-6 and IL-1β and the anti-inflammatory IL-10. The former cytokines are known to
induce acute inflammation of the peritoneum(19;20) and are correlated with adverse outcome(21-23),
whereas the latter is known to suppress the production of pro-inflammatory cytokines(19). At 24 h 
after induction of peritonitis, when a strong local inflammatory reaction may be expected, significant 
concentrations of all cytokines are indeed present in the abdominal fluid. At this time point the 
systemic reaction is much more subdued as reflected by the far lower plasma concentrations for 
IL-6 while TNF-α was even absent from the circulation. It may be that these cytokines are cleared
much quicker from the blood stream than from the peritoneal cavity. Also, the peritoneal cavity may
be a source of protracted cytokine production. 
Several other groups have studied the local and systemic inflammatory effects of bacterial peritonitis.
Sewnath induced peritonitis by a single intraperitoneal injection of a E. coli /saline suspension(24).
Montravers used a gelatin capsule filled with a mixture of  E. coli and B. fragilis and added barium 
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sulphate(25). The group of Martineau employed a 12 h continuous intra-abdominal  infusion with a
E. coli/fecal suspension(26). Although these studies differ considerably from each other and ours 
regarding the way of inducing peritonitis and the dose of bacteria given, the results are rather con-
sistent. Strongly elevated TNF-α and IL-6 levels in the abdominal fluid within 24 h after instillation
of the bacteria are found together with a much lesser increase in plasma levels of both cytokines. 
In our model both local and systemic IL-6 and TNF-α levels were lower than those reported in the 
studies mentioned above. This may in part be explained by dilution, since we took the peritoneal
samples after instillation of 5 ml normal saline in the abdomen. 
The elevated cytokine levels in the rats that received fecal suspension alone probably are the result
of the  endotoxin present.  A semi-quantitative analysis of the suspension confirmed the presence of
significant concentrations of lipopolysaccharide (data not shown). It may seem somewhat surprising
that, at least after 24 h, peritoneal cytokine levels were similar in the control group and the groups
receiving increasing doses of E. coli. Interestingly, at 72 h, when the cytokine levels are reduced and
clinical signs of illness strongly decreased, there seems to be a certain degree of correlation between
bacterial load and abdominal cytokine concentration. It may be that, during the first phase of illness,
locally produced LPS binding protein, which is an essential component in the innate immune 
response to E. coli peritonitis(27;28), is able to reduce the free endotoxin to similar levels in the 
different groups. As a consequence, mortality does not correlate with the local concentration of 
inflammatory mediators but seems to be linked to the bacterial counts in the circulation, as measu-
red after both 6 and 24 h. 
The present model has provided satisfactory results regarding abscess formation, survival and local
cytokine response in an animal model for secondary peritonitis. This model is suitable to study the
mechanisms involved in intra-abdominal  abscess formation after surgical treatment of generalized
peritonitis. Further experiments will be directed at fibrinolytic therapy as a means to reduce, and
possibly prevent, the formation of persisting abscesses.
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Chapter 3
Tissue-type plasminogen activator prevents
formation of intra-abdominal abscesses after
surgical treatment of secondary peritonitis
in a rat model
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ABSTRACT
Background
Optimal therapy of secondary peritonitis frequently results in the formation of residual abscesses,
which bear a substantial mortality and morbidity. This study aims to prove that fibrinolytic therapy
with recombinant tissue plasminogen activator (rtPA) can reduce abscess formation after surgical 
treatment of secondary peritonitis in a rat model, without causing unwanted side-effects.
Methods: 
Male Wistar rats received an intra-abdominal injection with a suspension of sterile feces, 105 cfu E. coli
and 104 cfu B. fragilis. Surgical debridement was performed 1 h after inoculation. Animals were 
randomized into 4 groups (n=14 each). Three groups received human rtPA at 1 h (rtPA1), 1 h and 6 h
(rtPA2) and 1, 6 and 24 h (rtPA3), respectively. Each dose contained 1.25 mg rtPA. Controls received 
saline only.  Animals were killed after 5 days.
Results: 
rtPA treatment reduced abscess formation in surviving animals, depending on number of doses given.
Animals in group rtPA3 had no abscesses in contrast to 88% of the controls  (mean 3.6 ± 2.7 abscesses
per rat; p<0.05). In the rtPA1 and rtPA2 group frequency of abscess formation was 58% and 33%, 
respectively. Mortality, course of body weight and bacteremia were not affected by rtPA and neither
were peritoneal cell counts and levels of TNF-α, IL-1β, IL-6 and IL-10. No bleeding complications were
observed.
Conclusions: 
rtPA  reduces intra-abdominal abscess formation after surgical treatment of generalized peritonitis
without increasing mortality or affecting the local inflammatory response.
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INTRODUCTION
Secondary peritonitis, which is by far the most common form of peritonitis, results from the loss of
integrity of the gastrointestinal or genitourinary tract, leading to contamination of the peritoneal
space(1). Despite improved diagnostic modalities, potent antibiotics, modern intensive care, and 
aggresive surgical treatment, up to one third of patients still die from generalized peritonitis(2;3).
Removal of the source of contamination, debridement of the abdominal cavity and drainage of 
abscesses are the cornerstones of successful surgical therapy in generalized peritonitis. Antibiotics
reduce the general effects of sepsis and infectious complications(4;5). However, optimal therapy 
including antibiotic treatment results in the formation of residual abscesses in a considerable number
of cases, which bear a substantial mortality and morbidity(3;6).
In peritonitis both the coagulation and fibrinolytic cascade are upregulated. In the early phase of 
peritonitis, coagulation dominates, resulting in the formation of fibrin in the abdominal cavity. These
fibrin deposits contain viable bacteria that become unreachable for the local immune defenses in the
abdominal cavity and for antibiotics(7;8). Hence, these contaminated fibrin clots form the nidus for
intra-abdominal  abcesses(8). In addition, fibrin deposits may become infiltrated by fibrocytes and 
become fibrous adhesions which by itself may result in considerable morbidity and even mortality(9).
Thus, well-timed therapy aiming at restoration of intraperitoneal fibrinolytic capacity may  prevent
the formation of residual abscesses and adhesions.
Tissue-type plasminogen activator (tPA), the main physiological plasminogen activator, has been
applied as a fibrin-specific thrombolytic agent for the treatment of thromboembolic diseases(10).
For instance, tPA has been succesfully applied for the treatment of ischemic stroke(11) pulmonary
embolism(12) and catheter thrombosis(13). Its recombinant form, rtPA, has been proven effective in
the treatment of pleural empyema(14) and in two clinical cases of peritonitis(15;16). 
The rationale behind the use of rtPA in peritonitis is early breakdown of fibrin clots to eliminate the
nidus for residual abscesses, without the risk of hemorrhage due to systemic activation of plasmi-
nogen activator inhibitor as a result of sepsis. In previous experimental studies, rtPA was effective in
reducing abscess formation in rodent models of peritonitis without any apparent increase in blee-
ding complications(17;18). However, reduced abscess formation was associated with a considerable
and significantly increased mortality, which may be due to release of bacteria from the abdominal
cavity, leading to bacteriaemia, sepsis and/or an exaggarated local immune response(17;19). The 
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present study was initiated to determine whether the effect of intra-abdominal  application of rtPA
can be optimized by  changing the method of application and the dosage scheme. In addition, it was
studied whether intraperitoneal rtPA therapy is associated with an increased inflammatory response
in the abdominal cavity, increased incidence and severity of bacteriaemia or mortality.
MATERIALS AND METHODS
Experimental design
Fifty-five animals were randomly divided into three groups of 14 and one group of 13 rats. Peritonitis
was induced in all rats by intraperitoneal injection of 2 ml of a fecal suspension containing 104 cfu B.
fragilis (from a clinical isolate) and 105 cfu E. coli (strain 25922 from the American Type Culture Col-
lection), respectively(20).
One hour after inoculation, the rats were anesthetized by inhalation of a mixture of isoflurane-
oxygen-nitrous oxide. The abdominal cavity was debrided including a partial resection of grossly 
contaminated omentum and rinsed with 5 ml of sterile saline of 380C. The abdomen was closed with
a running suture of 4.0 Polyglactin 910 (Ethicon, The Netherlands), the skin was closed with staples.
Rats received 5 ml normal saline subcutaneously for resuscitation.
Three experimental groups received intraperitoneal  injections with recombinant human tPA at 1 h
(rtPA1), 1 h and 6 h (rtPA2) and 1, 6 and 24 h (rtPA3) after inoculation, respectively. Each dose consisted
of 1.25 mg rtPA (Actilyse®, Boehringer Ingelheim, Germany) in 2.5 ml saline. The animals in the fourth
group (control) received sterile saline only at each time point. Those in the rtPA1 and rtPA2 groups 
received saline at the time points that they were not treated with rtPA.
Blood samples were taken at 6 and 24 h after inoculation by orbital puncture. Peritoneal fluid sam-
ples were taken after 24h via a laparotomy. After 5 days the animals were killed by CO2 asphyxiation.
The abdomen was inspected, with particular attention to the number and location of abscesses. 
All fibrin encased purulent collections were considered to represent abscesses. The presence of either
diffuse purulent abdominal fluid, diffuse redness and edema of the peritoneum or diffuse adhesion
of intra-abdominal organs was considered indicative of generalized peritonitis.
Animals
Male Wistar rats weighing 250-280 g (Harlan BV, Horst, the Netherlands) were housed two per cage
Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after... 41
and accustomed to laboratory conditions for five days before the start of the experiment. All animals
were weighed daily and had free access to water and standard rodent chow throughout the entire
experimental period (Hope Farms, Woerden, the Netherlands). The Animal Ethics Review Committee
of the Radboud University Nijmegen approved the study.
Sample collection
At 6 and 24 h after bacterial inoculation, 1 ml blood samples were taken by orbital plexus puncture,
under anaesthesia, and collected in tubes containing 50 IU heparin for bacterial culturing.  Peritoneal
fluid samples were also collected under anaesthesia at 24 h after bacterial inoculation. After reope-
ning the abdomen, 5 ml of sterile saline of 380C was installed in the abdominal cavity. The abdomen
was gently massaged and at least 2 ml of fluid was withdrawn. The samples were centrifuged for 10
min at 2000 rpm and supernatants stored at -800C until further analysis.
Sample analysis
Heparinized blood samples (300 µl) were cultured for the presence of E. coli. Serial dilutions in Brain
Heart Infusion broth were plated onto MacConkey blood agar plates. After 24 and 48 h of incubation
at 370C bacteria were identified and counted. 
Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and interleukin-10 (IL-10)
were measured in peritoneal fluid. All assays were performed using commercially available ELISA kits
(Endogen®, Pierce Biotechnology Inc, Rockford IL, USA). According to the manufacturer, the sensitivi-
ties for the various assays were < 10 pg/ml for TNF-α, < 12 pg/ml for IL-1β, < 16 pg/ml for IL-6 and < 3
pg/ml for IL-10, respectively. Cells were counted in peritoneal fluid after dilution of the sediment with
saline (to a concentration of 50.000 cells/ml) and staining with May-Grunwald Giemsa reagent.
Statistics
Statistical analysis was performed using one-way ANOVA and Tukey Kramer multiple comparison
test for multiple group comparison. Kruskal-Wallis and Mann-Whitney test were applied to process
nonparametric data. Mortality rates were compared using a log rank test. Trend analysis for the 
parameters concerning abscess formation was performed using a Pearson chi square test and COX
regression. P values < 0.05 were considered to be significant.
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RESULTS
Abscesses
Recombinant t-PA treatment reduced abscess formation in animals which survived for 5 days (Figure
1A). The percentage of rats with abscesses gradually decreased from 88% in the untreated control
group to 0% in the rtPA3 group. The mean number of abscesses per rat gradually decreased from 3.6
± 2.7 (mean ± SD) in the controls to 0 in the rtPA3 group (p = 0.003, Figure 1B).
For both parameters, the percentage of rats with abcesses and the number of abcesses per rat, 
statistical analysis showed a significant trend for abscess reduction with the increasing number of
rtPA doses given (Pearson Chi square, p=0.004 and COX regression, p<0.0001).
Blood cultures
Positive blood cultures (Table 1) were found in 50-79% of the rats after 6 h and in 73-90% of the rats
after 24 h. No differences were found between control rats and rtPA treated rats, irrespective of the
dose of rtPA given. Altogether, at 24 h the mean concentrations of E. coli were significantly (p<0.05)
higher than at 6 h: 31.103 (range: 0.1-281 .103) cfu/ml and 275 (range: 40-1800) cfu/ml, respectively. 
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Figure 1a en 1b. Abscess formation in surviving animals.
Percentage of rats with abscesses (A) and mean number of abscesses per rat (B). * significant (p<0.05) difference between groups. The numbers within the 
columns in A indicate the actual number of rats with abscesses (represented as black bars) versus the total number of survivors in that group. 
A B
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Cells and cytokines
One day after inoculation, cells in the abdominal fluid were predominantly neutrophils and, to a 
lesser extent, macrophages (Figure 2). The relative distribution over the various cell types remained
unaffected by rtPA treatment. Also, the absolute numbers of cells were the same in the various groups
(results not shown). Bacterial inoculation induced significant concentrations of various inflammatory
cytokines in the abdominal fluid. Figure 3A-D shows the levels of respectively TNF-α,  IL-1β, IL-6 and
IL-10, as measured 24 h after inoculation. For none of these cytokines, treatment with any regimen
of rtPA led to significant changes.
Clinical course and survival
All rats became severely ill after inoculation, as characterized by lack of movement, erect body hair
and anorexia. Body weight decreased significantly (p<0.05) over the first 24 h after inoculation and
stabilized thereafter. The changes in body weight during the experimental period (figure 4) were 
similar in the four groups. No bleeding complications were observed in any of the groups.
The overall survival rate was 62%. The rats that did not survive until the end of the experiment died
mainly during the first 48 h after inoculation. The mortality rates of the experimental and control
groups were similar. In all control rats with abscesses all three signs of generalized peritonitis were
still present at autopsy 5 days after inoculation. In the rtPA treated rats with abscesses mostly just one
sign of peritonitis was observed confined to one local area of inflammation.
Group % positive cultures cfu/ml cfu/ml
6 h 24 h 6 h 24 h  
C 79 82 200 (40-1000) 60.103 (0.1-281.103)
rtPA1 69 85 90 (40-740) 28.103 (0.2-281.103) 
rtPA2 79 90 170 (60-1360) 22.103 (1-185.103)
rtPA3 50 73 640 (40-1800) 15.103 (0.6- 57.103)
Table 1. Blood cultures.
Blood samples were cultured for the presence of E. coli at both 6 and 24 h after inoculation. Data pertain to the percentage (of all samples taken) which
was positive for E. coli and to the median (and range) of the concentrations in the positive samples.
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Figure 4.
Course of body weight during the experimental period after bacterial
inoculation at day 0:     , controls;     , rtPA1;     , rtPA2;     , rtPA3. 
Figure 3. Cytokines in abdominal fluid.
Cytokine concentrations in pg/ml in peritoneal fluid collected at 24 after
inoculation in animals surviving for 5 days. Data are depicted as medians
with 25-75 percentiles in boxes and 5-95 percentiles represented as ver-
tical lines. A = TNF-α, B = IL-1β, C = IL-6, D = IL-10
Figure 2. Differential cell counts in abdominal fluid.
Samples were taken at 24h after inoculation. Data on each cell type are
expressed (mean + SD) as percentage of the total cell count.     neutro-
phils,     eosinophils,     macrophage-type cells,     lymphocytes.
A
B
C
D
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DISCUSSION
Intensifying fibrinolytic therapy after surgical debridement  significantly improves the outcome in rats
with secondary peritonitis without increasing morbidity or mortality. Intraperitoneal inoculation of
a suspension of sterilized faeces with  Escherichia coli (E. coli) and Bacteroides fragilis (B. fragilis) con-
stitutes a valid animal model mimicking secondary peritonitis(21). Surgical debridement after 1 h 
provides a reproducible model to study residual abscesses after surgical treatment of generalized
peritonitis(20). All animals from the control group displayed clear signs of a diffuse, generalized 
peritonitis at autopsy. The 1 h period between inoculation of the fecal suspension and surgical inter-
vention is short, but a further delay results in an unacceptably high mortality when no antibiotics are
administered(22). Although antibiotics are highly important as an adjunct to surgical therapy, we
have chosen not to use antibiotics in the present experiment in order to study exclusively and 
selectively the potential of rtPA to act as an adjuvant to surgical therapy. 
While hyaluronic acid and fungal polysaccharides have recently been shown to prevent abscess (and
adhesion) formation in a rat peritonitis model, rtPA appears to be more effective(23;24). Rotstein and
Kao studied the effect of  a single dose of rtPA  adminstered immediately after implantation of a a
fibrin clot containing E. coli and B. fragilis(25). Our own group applied a single dose of rtPA in a slow
release cellulose carrier immediately after surgical debridement for secondary peritonitis in a model
which was similar to the one used in the present experiment(17). In both experimental conditions,
where the same bacteria were inoculated but the timing of rtPA treatment was essentially different,
a single application of a rtPA formula led to a reduction in abcess formation. The present experiment
demonstrates that three doses rtPA in saline administered in the first 24 h after bacterial inoculation
and surgical debridement are more effective than a single injection. Thus, the best effect of rtPA is
achieved when treatment is given over, at least, the entire first 24 h after bacterial inoculation. 
Adhesion formation was not an endpoint in this study. Therefore, adhesions were not actually scored
or quantified. Yet, we did observe that in the vast majority of the rats treated with rtPA, the abdominal
fluid was remarkably clear and the intra-abdominal organs were not adherent to each other while
in the untreated rats adhesions occurred almost invariably. 
RtPA is fibrin-specific(10) and has a half-life of 4-5 minutes in plasma (product information by 
Boeringer-Ingelheim). Yet the process of decreased fibrinolytic activity and increased coagulation in
the abdominal compartment is considered to last during the course of peritonitis(26;27), but at least
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for 12 h after inducing peritonitis in a rat model(28). Hence, a single dose of rtPA is not likely to 
completely reverse the disturbed balance between intra-abdominal  fibrinolysis and coagulation.
The dose of rtPA applied in this study (approximately 4.1 mg/kg body weight for each dose given)
has been chosen empirically, partly based on the results in prior experiments performed by van Goor
et al.(17;29;30). The authors reported that coagulation activity rate in the rat is elevated by a factor
2.7 compared to man(29). It remains to be established how this dose compares to those given in 
clinical cases of peritonitis, where intraperitoneal doses of 0.5 and approximately 0.08 mg/kg body
weight have been described in two case reports. In the first case rtPA was administered after repeat
laparotomy in a neonate(15). The second report concerns the use of rtPA after a third episode of CAPD
peritonitis(16). Although in these cases intra-abdominal  fibrinolysis was pursued in a completely
different situation, i.e. tertiary peritonitis, the data do suggest that lower doses than those used by
us could be effective.
In the current study we observed no statistically differences in mortality  between groups. This is in
apparent contrast to both previous studies in rats with experimental abcesses or fecal peritonitis
mentioned before(17;25), where a major concern has been that rtPA treatment was associated with
significantly and seriously increased mortality. A possible explanation could be that rtPA induces an
exaggerated local inflammatory (cellular and cytokine) or systemic response, but so far no data to this
extent have been available. In animal models of bacterial peritonitis the inflammatory response has
been characterized by highly elevated peritoneal levels of cytokines with a much lesser increase of
systemic inflammatory mediators(31-33). On the cellular level, fecal peritonitis evokes an early influx
of neutrophils followed by an influx of macrophages (34-36). 
The peritoneal cytokine levels and the cell counts measured in the untreated control group of the pre-
sent study are completely in line with expectations based on the data mentioned above. Moreover,
since these parameters are similar in control and rtPA-treated animals, our data appear to exclude any
significant effect of rtPA on local inflammation. Also, rtPA does not affect bacteremia. In addition, it
is also noteworthy that neither local nor systemic bleeding complications, as a potentially major 
adverse effect of fibrinolytic therapy, have been observed. Systemic effects are unlikely in the first
place since systemic uptake of rtPA after intraperitoneal delivery in the rat appears to be insignificant
(30). In addition, the high systemic PAI levels, which have been described in peritonitis, will most 
likely counteract the systemic effects of rt-PA(30).
Thus, in the present model of fecal peritonitis, intra-abdominal  application of rtPA over the first 24
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h after surgical debridement is very effective in preventing the formation of intra-abdominal abces-
ses. The therapy is not associated with adverse events such as an increased local inflammatory res-
ponse and/or increased mortality. We suggest that further research into its therapeutic efficacy and
suitability in clinical application for the treatment of secondary peritonitis is warranted.
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Chapter 4
Both tissue-type plasminogen activator and
urokinase prevent intra-abdominal abscess
formation after surgical treatment of peri-
tonitis in the rat
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ABSTRACT
Background
Prevention of intra-abdominal abscess formation constitutes an important goal in treatment of 
secondary peritonitis. Fibrinolytic therapy may be effective in this respect. The efficacy of recombinant
tissue plasminogen activator (rtPA) and urokinase is compared in a preclinical model for surgical treat-
ment of peritonitis.
Methods
Peritonitis was induced by intraperitoneal bacterial challenge in male Wistar rats. One hour after-
wards, surgery was performed. Four groups (n=20) were treated with either rtPA, urokinase, strepto-
kinase (a negative protein control) or saline. Blood cultures were taken at 6 and 24 h; cell counts and
cytokine measurements were performed in peritoneal fluid at 1, 3 and 5 days. After 5 days, animals
were killed and intraperitoneal abscess formation was analyzed.
Results
Both rtPA and urokinase strongly (by > 75%) and significantly (p<0.05) reduced abscess formation
without negative side effects. No bleeding complications were observed. Fibrinolytic therapy altered
the intraperitoneal cellular distribution (less neutrophils and more macrophages) but did not 
essentially alter courses of interleukin-6 and interleukin-10 (decreasing in time) or TNF-α (increasing
in time) levels.
Conclusion
Both rtPA and urokinase effectively and safely reduce abscess formation in a rat model for treatment
of secondary peritonitis. Fibrinolytic therapy should be further developed for clinical application.
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INTRODUCTION
Secondary peritonitis results from contamination of the abdominal cavity with gastro-intestinal con-
tents, in the majority of cases caused by perforation of the gastro-intestinal tract. Despite optimal
treatment, invariably including surgical intervention, organ-supportive care and antibiotic therapy,
peritonitis remains an important cause of morbidity and mortality in surgical practice and in the 
intensive care unit(1-3). One of the sequelae of peritonitis is the formation of intra-abdominal ab-
scesses. Drainage is the preferred treatment and can be performed either surgical or percutaneously.
By either means, abscess drainage will be successful in approximately 70% of all cases (4). However,
surgical treatment i.e. reexploration by laparotomy, contributes to increased short- and long-term
morbidity (5). In addition, abscesses recur in 10% of treated cases(6). Therefore, prevention of abscess
formation is an important goal in the search for the optimal treatment of generalized peritonitis. 
Intra-abdominal  abscesses originate from contaminated fibrin clots. Fibrin deposition occurs in the
abdominal cavity as a result of a disturbed balance between fibrinogenesis and fibrinolysis, due to
mesothelial cell damage. Bacteria caught in fibrin clots cannot be reached by antibiotics or the 
immunologic defence systems in the abdominal cavity and thus form the nidus for intra-abdominal
abscess formation. Fibrinolytic therapy may therefore be an attractive adjuvant therapy to diminish
the risk of abscess formation. 
There is little information about the clinical application of fibrinolytics in peritonitis. Thrombolytic
agents administered intraperitoneally appear to facilitate antibiotic penetration into the bio film
formed by certain bacteria (7;8). Numerous case reports of intraperitoneal thrombolytic adjunctive
therapy for recurrent or persistent peritoneal dialysis-associated peritonitis  have indicated that these
agents may have a role in the treatment of selected patients(8;9). Next to tissue-type plasminogen
activator (tPA), the fibrinolytic enzymes urokinase and streptokinase are widely used in clinical prac-
tice to install thrombolytic therapy(10-12). 
Earlier preclinical studies by us(13) and others(14) have indeed indicated the potential of exogenous
tPA to reduce intraperitoneal abscess formation during generalized peritonitis. Recently, we have 
optimized a model in the rat to study abscess formation after induced intra-abdominal  infection(15)
and initiated a series of experiments aiming to establish that fibrinolytic therapy can be conducted
effectively and safely. In a dose-finding study of limited size, using small groups of rats, we have first
established ‘proof of principle’, by demonstrating that repeated intraperitoneal injection of human
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recombinant tPA (rtPA) can lead to a significant reduction of abscess formation(16). The present 
experiment focuses on the efficacy and safety of two differently acting fibrinolytic drugs in a model
which shares important, but not all, features with the clinical (surgical) treatment of secondary 
peritonitis. For instance, antibiotics were deliberately not given at the present stage. We hypothesized
that both rtPA and urokinase can be used intraperitoneally to reduce abscess formation without 
inducing potential side-effects such as bacteriaemia, mortality and bleeding complications. 
MATERIALS AND METHODS
Experimental design
Eighty rats were randomly divided into four groups of twenty rats. Peritonitis was induced in all rats
by intraperitoneal injection of 2 ml of a faecal suspension containing 104 cfu Bacteroides fragilis
(strain 25285 from the American Type Culture Collection) and 105 cfu Escherichia coli (strain 25922
from the American Type Culture Collection), respectively(16) . One hour after inoculation surgery was
performed. The rats were anesthetized by inhalation of a mixture of isoflurane-oxygen-nitrous oxide.
The abdominal cavity was debrided including partial resection of macroscopically polluted omentum
and rinsed with 5 ml of normal saline of 380C. The abdomen was closed with a running suture of 4.0
Polyglactin 910 (Vicryl®, Ethicon,  Amersfoort, The Netherlands), the skin was closed with staples.  Rats
received 5 ml normal saline subcutaneously for resuscitation.
In two experimental groups, either rtPA (Actilyse®, Boehringer Ingelheim, Germany) in a dose of 1.25
mg in 2.5 ml saline or Urokinase (Urokinase®, MEDAC, Hamburg) in a dose of 725.000 IU in 2.5 ml 
saline was installed in the abdomen at the end of surgery (1h), at 6 h via percutaneous injection and
at 24 h via relaparotomy. At these same time points the two control groups received either 2.5 ml of
normal saline or streptokinase (Streptase®, Aventis Pharma BV, Hoevelaken) in a dose of 725.000 IU
in 2.5 ml saline. The streptokinase group has been added as a negative protein control since strepto-
kinase does not affect the rat coagulatory system(17).
After 5 days the animals were killed by CO2 asphyxiation. The abdomen was inspected, with particular
attention to the number and location of abscesses as well as to signs of intra-abdominal bleeding.
All fibrin-encased purulent collections were considered to represent abscesses. The presence of 
diffuse purulent abdominal fluid, diffuse redness, and edema of the peritoneum was considered 
indicative of generalized peritonitis. The investigator was blinded for the therapy given.
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Animals
Male Wistar rats weighing 250-280 g (Harlan BV, Horst, the Netherlands) were housed two per cage
and accustomed to laboratory conditions for five days before the start of the experiment. All animals
were weighed daily and had free access to water and standard rodent chow throughout the entire
experimental period (Hope Farms, Woerden, the Netherlands). The Animal Ethics Review Committee
of the Radboud University Nijmegen approved the study.
Sample collection
Six and 24 h after inducing peritonitis, 300 µl blood samples were taken from all rats by orbital plexus
puncture under general anesthesia, and collected in tubes containing 50 IU heparin for bacterial cul-
turing. Peritoneal fluid samples were collected from all animals under general anesthesia, at 24, 72
and 120 h after bacterial inoculation as follows: after removing two skin staples and one abdominal
wall stitch to gain access, 5 ml of sterile saline of 380C was installed in the abdominal cavity and at
least 2 ml of fluid were withdrawn. The samples were centrifuged for 10 min at 750 x g and super-
natants stored at -800C.
Sample analysis
Heparinized blood samples (300 µl) were cultured for the presence of E. coli. Serial dilutions in Brain
Heart Infusion broth were plated onto MacConkey blood agar plates. After 24 and 48 h of incubation
at 370C bacteria were identified and counted.  Levels of tumor necrosis factor-α (TNF-α), interleukin-
6 (IL-6) and interleukin-10 (IL-10) were measured in peritoneal fluid by using commercially available
ELISA kits (Endogen®, Pierce Biotechnology Inc, Rockford IL, USA). According to the manufacturer, the
sensitivities for the assays were <10 pg/ml for TNF-α, <16 pg/ml for IL-6 and <3 pg/ml for IL-10, 
respectively. Cells were counted in peritoneal fluid after dilution of the sediment with saline (to a
concentration of 50.000 cells/ml) and staining with May-Grunwald Giemsa reagent.
Statistics
Statistical analysis was performed using one-way ANOVA and Tukey-Kramer multiple comparison test
for parametric data, while a Kruskal-Wallis followed by Dunn’s multiple comparison test were applied
to process nonparametric data. Trend analysis for the parameters concerning abscess formation was
performed using a Chi-square test and COX regression. P values < 0.05 were considered significant.
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RESULTS
Survival and clinical course
Two out of 80 animals died within 48 hours after inducing peritonitis, both in the urokinase group.
Septic shock was believed to be the probable cause of death since no abdominal cause could be iden-
tified. No further mortality was observed during the study. Altogether, there was no significant 
difference between groups regarding mortality.
All rats became severely ill after inoculation, as characterized by lack of movement, pilo-erection and
anorexia. Body weight decreased during the first 24 h after inoculation and stabilized thereafter. The
changes in body weight during the experimental period (Figure 1) were similar in the four groups. 
Almost invariably, all signs of generalized peritonitis were observed at post mortem examination,
both in untreated rats and those treated with streptokinase. No bleeding complications were 
observed in any of the animals. 
Abscesses
Both rtPA and urokinase treatment significantly reduced abscesses formation as compared to the
controls and the streptokinase treated group. The percentage of surviving rats with abscesses was sig-
nificantly lower in the groups treated with rtPA and urokinase than in both control and streptokinase
groups: 55 % vs. 100 % (p<0.0001, Chi-square test) (Figure 2A). 
The mean number (± SD) of abscesses per rat was1.4 ±1.9 and 0.9 ± 1.1 in the rtPA and urokinase group
versus 4.9 ± 1.9 and 5.6 ± 2.3 in the control and streptokinase group, respectively (Figure 2B). The 
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Figure 1. Blood cultures at 24 hours after inoculation.
Course of body weight during the experimental period after bacterial ino-
culation at day 0. : controls; : streptokinase; : rtPA; : urokinase. 
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Figure 2a en 2b. Abscess formation in surviving animals.
Percentage of surviving rats with abscesses (A) and mean (+ SD) number of abscesses per rat (B). The numbers within the columns in A indicate the actual num-
ber of rats with abscesses (represented as black bars) versus the total number of survivors in that group. Data are depicted as medians with 25-75 percentiles
in boxes and 5-95 percentiles represented as vertical lines *: significant (p<0.05, A: Chi-square test; B: Kruskal-Wallis plus Dunn’s test ) difference between groups.
number of rats with abscesses in the diaphragmatic region was significantly lower in the rtPA and
urokinase groups than in the control and streptokinase groups (Table 1): 3 and 4 versus 17 en 19, 
respectively (p<0.0001, Chi-square). The same was noted, to a lesser extent, in the left paracolic 
region: 4 and 1 versus 10 and 6, respectively (p<0.01, Chi-square).
n Diaphragm Left paracolic Right paracolic
Controls 20 17 10 14
Streptokinase 20 19 6 18
rtPA 20 3* 4 10
Urokinase 18 4* 1** 8
Table 1. Distribution of abscesses.
Each column displays the number of rats in each group with abscesses in one of the three locations, where abscess formation was observed most 
frequently. Some rats had abscesses at multiple locations. * p<0.05 (Chi-square test) vs both controls and streptokinase groups. ** p<0.05 vs controls. 
A B
Both tissue-type plasminogen activator and urokinase prevent intra-abdominal abscess... 61
Group % positive cultures cfu/ml cfu/ml
6 h 24 h 6 h 24 h  
Controls 40 74 220 (20-24.103) 570 (20-78.103)
Streptokinase 50 85 2360 (20-17.103) 660 (20-67.10v)
rtPA 45 80 300 (20-11.103) 680 (20-70.103)
Urokinase 40 63 100 (20-11.103) 160 (20-67.103)
Table 2. Blood cultures.
Blood samples were cultured for the presence of E. coli at both 6 and 24 h after inoculation. Data pertain to the percentage (of all samples taken), which
was positive for E. coli and to the median (and range) of the concentrations in the positive samples.
Figure 3. Blood cultures at 24 hours after inoculation.
Each symbol represents a concentration of bacteria expressed as number
of colony forming units per ml. Horizontal lines indicate median values
in each group.
Blood cultures
Positive blood cultures were found in 40-50% of all rats at 6 h after inoculation and this frequency
was significantly increased within each group at 24 h (p<0.05, Chi-square, Table 2). There were no 
significant differences between the groups at either time point. 
There was a large variation between animals regarding the concentration of E. coli and no significant
differences between the groups (Figure 3). The median concentration of cultured E. coli cfu/ml, (Table
2) was significantly (p< 0.05) higher in the surviving animals at 24 h than at 6 h, in all groups except
the streptokinase group. 
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Cells and cytokines
Since streptokinase treatment had no effect whatsoever on abscess formation, which was the primary
outcome parameter in this study, quantification of cell numbers and cytokine concentrations was
only performed in the two experimental groups and the saline control group.
For all groups, the absolute number of cells counted in the peritoneal fluid declined after 72 h. 
However, it did not differ between groups at any time point. Differential cell count of peritoneal fluid
showed predominantly neutrophils at 24 h. Thereafter neutrophil numbers decreased, while the 
relative presence of the other cell types increased. Generally speaking, fibrinolytic therapy resulted
in less neutrophils and lymphocytes and more macrophages and eosinophils in time (Figure 4).
Significant (p<0.05, ANOVA plus Tukey-Kramer) differences between the three groups were only 
encountered in neutrophil and macrophage counts. Neutrophil counts in the controls were higher
than in the rtPA group at 24 h and higher than in both experimental groups at 72 and 120 h. The same
trend was observed for lymphocytes. Contrarily, macrophage counts in the control group remained
significantly below those in the rtPA group at 24 and 72 h and below those in both experimental
groups at 120 h. The same was observed for eosinophils but not significantly so. No significant diffe-
rences whatsoever were found between the rtPA and urokinase groups
For all groups, peritoneal fluid IL-6 and IL-10 concentrations were highest at 24 h and lowest at 120 h
(Figure 5). At 24 h, these cytokine levels ranged widely, upper levels reaching nearly 5000 and 1700
pg/ml for IL-6 and IL-10, respectively. At none of the time points investigated did IL-6 concentrations
differ significantly between the three groups. For IL-10, there were no differences at 24 h, but at both
72 and 120 h levels in the control group remained significantly (p<0.05, Kruskal-Wallis and Dunn’s
multiple comparison test) higher than in the urokinase group.
On the average, bacterial inoculation led to measurable TNF-α concentrations 24 h later, which were
similar in all groups. In contrast to the interleukins, TNF-α increased with time and levels at 120 h
were significantly higher in all groups. At this time, concentrations in the rtPA group were signifi-
cantly lower than those in the control group.
In order to investigate possible mediators which contribute to abscess formation, we compared the
cytokine levels and cellular counts in all rats (from control and both experimental groups) which
showed abscesses and those that were free of abscesses at autopsy. At none of the time points 
significant differences were found.
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Figure 4. Differential cell counts in abdominal fluid. 
A: neutrophils, B: macrophages, C: eosinophils, D: lymphocytes. Data on
each cell type are expressed (n=10, mean + SD) as percentage of the total
cell count,     : controls;     : rtPA;     : urokinase. *: significant (p<0.05, ANOVA)
difference between groups.
Figure 5. Cytokines in abdominal fluid. 
Data for IL-6 (A), IL-10 (B) and TNF-α (C) are depicted as medians (measu-
rements in all surviving animals) with 25-75 percentiles in boxes and 5-
95 percentiles represented as vertical lines. *: significant (p<0.05, Kruskal-
Wallis plus Dunn’s test) difference between groups.
A
B
C
D
A
B
C
64 chapter 4
DISCUSSION
Intra-abdominal  application of rtPA or urokinase significantly reduces the number of abscesses in the
abdominal cavity in rats with generalized peritonitis. The streptokinase group has been added as a
negative protein control since streptokinase does not affect the rat coagulatory system(17). The fact
that this group behaves similarly to the saline controls supports the conclusion that the effect of
both exogenous rtPA and urokinase is a specific one.
The animal model used, is a modification of a well-established procedure(15;16) to induce generalized
peritonitis. It consistently reflects several aspects of peritonitis as observed in the clinical situation
with transiently elevated cytokine levels and typical changes in the cellular composition of the 
peritoneal fluid. After surgical intervention, signs of local and generalized peritonitis remain present
for an extended period and rats will almost invariably develop intra-abdominal  abscesses. These 
abscesses are typically found in the sub diaphragmatic and paracolic spaces. It should be emphasized
that the ultimate goal of our series of experiments is to optimize the treatment of generalized peri-
tonitis by intra-abdominal  application of fibrinolytics. As yet, we do not purport to present a model
that reflects the clinical situation of peritonitis in all its aspects. Here, we focus on prevention of ab-
scess formation and thus mortality is not an essential feature of the model(15). In addition, although
we recognize antibiotic therapy to be highly important as an adjunct to surgery, we have chosen to
not (yet) use antibiotics in order to assess exclusively and selectively the potential of fibrinolytics to
act as an adjuvant to surgical therapy. Still, antibiotics are especially helpful in treating the systemic
effects of peritonitis, while, to our knowledge, a beneficial effect on abscess formation has not been
documented. In a pilot study we have established that a regimen of metronidazole and ceftriaxone
does not reduce abscess formation in our rat model (unpublished data). 
The two-edged effect of fibrin formation has been recognized already in the early 1980s. On one
hand, fibrin prevents dissemination of bacteria throughout the abdominal cavity. On the other hand,
fibrin protects bacteria from the immunologic defenses, thus forming a nidus for abscess formation
and ongoing intra-abdominal  sepsis(18;19). Performing surgery itself reduces peritoneal tPA activity
and thus can be a trigger for fibrin formation in the abdominal cavity(20;21). The present model com-
prises repeated laparotomies, essential to collect samples of peritoneal fluid. By limiting the size of
the laparotomy as much as possible we have tried to limit its influence. A factual investigation of
their effect falls outside the scope of the present experiment. Since the procedure is performed in all
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groups, the outcome of the present experiment will not be affected.
One could easily imagine fibrinolytic therapy to affect wound healing, and certainly so in the intestine,
although the existing literature(22-24) appears to be largely reassuring. Preliminary experiments in
our laboratory confirm that anastomotic healing is not affected under non-infectious conditions. 
Since fibrin formation is essential to the formation of both surgical adhesions and abscesses, therapy
directed at its prevention is thought to be potentially beneficial in the prevention of both complications.
However, anti-adhesive agents do not necessarily have any effect on abscess formation(25-27).
The potential usefulness of tPA has been suggested in the past, but its application mode used in
those peritonitis models has led to seriously enhanced mortality (13;14). This has been hypothesized
to be caused by a massive release of bacteria from infected fibrin clots, causing bacteremia, a 
modulated immune response or a combination of both. Bacterial cultures from intra-abdominal  
abscesses confirmed the local presence of bacteria, yet bacteremia could not be confirmed(13). In the
present experiment, fibrinolytic therapy does lead to neither mortality nor increased bacteremia.
The typical course in cellular response to abdominal inflammation and infection(28) is observed:
neutrophils are gradually replaced by macrophages and eosinophils. In both rtPA and urokinase
groups, a lower neutrophil (and lymphocyte) count together with a higher macrophage (and eosinophil)
count is observed with time, indicating a, quantitative rather than qualitative, modulation of the
local cellular response. Recent experiments, investigating the behaviour of tPA -/- mice in intra-
abdominal  sepsis, also suggest that there may be a role for tPA in the inflammatory cell recruitment
in the peritoneal cavity(29). The effects of fibrinolytic therapy on the peritoneal cytokine response are
also limited and quantitative rather than qualitative. The course of the IL-6 levels in all groups in this
study is as to be expected in peritonitis and is consistent with experimental data(16;30-32) that 
describe an elevation of IL-6 and TNF-α. Recent clinical data(33) report a significant elevation of Il-6,
IL-10 and TNF-α at the onset of disease with normalization at the 5th day. Altogether, the data on the
local inflammatory response do not suggest any major effect of rtPA or urokinase.
Recent experimental data support the thesis that manipulation of the intra-abdominal fibrinolytic
capacity can affect the course of disease in a cecal ligation and puncture model for polymicrobial 
peritonitis. Intra-abdominal  application of rtPA(34) results in an improved bacterial clearance but
no improvement of survival, while peritoneal lavage with activated protein C also may rebalance 
coagulation and fibrinolysis within compartments and improve survival(35). In addition, a reduced
local inflammatory response and improved survival have been observed after intra-abdominal 
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treatment with recombinant human antithrombin(36).
The clinical use of fibrinolytics is associated with bleeding complications in- or outside the operative
field(37;38). In septic rats, systemic bleeding is unlikely  because plasma levels of Plasminogen Acti-
vator Inhibitor (PAI) are elevated, consequently leading to the forming of inactive tPA-PAI com-
plexes(39) In addition, previous studies confirm that total plasminogen activity after intra-abdominal
application of tPA is very low(40). Indeed, no bleeding complications are seen in any of the rats from
the present study, either in the rtPA group or in the urokinase group.
The doses of urokinase and rtPA are based on their use in the clinical setting for treatment of
thrombo-embolic disorders(37;38), taking into consideration that the coagulation activity rate in the
rat is elevated by a factor 2.7 compared to man(17). In addition, the dose of rtPA as applied in the 
current study has already proven its value in earlier studies(13;40). The recent dose finding study 
has demonstrated that repeat doses at 1, 6 and 24 h yield the best results with respect to abscess 
reduction(16).
The use of urokinase in stead of rtPA may be advantageous. Firstly, the half-life of urokinase is four-
fold the half-life of rtPA. A longer-lasting effect may be advantageous in topical treatment if it 
lessens the number of doses needed to serve its purpose. However, further studies are needed to
prove this to be true since urokinase is less fibrin-specific than rtPA(38). Secondly, urokinase is less 
expensive than rtPA. Our results prove both fibrinolytics to be equally effective, although the use of
urokinase would lead to a 35% reduction of costs as compared to rtPA. As yet, there are no data on a
possible connection between dose and outcome parameters such as abscess reduction, morbidity
and mortality. 
In order to further determine optimal conditions for fibrinolytic therapy, the effects of lower doses
of these drugs and their effectiveness after prolonged or delayed administration will be investigated,
as well as their efficacy in the presence of antibiotics. We believe fibrinolytic agents to be very 
promising for clinical use in the treatment of secondary peritonitis.
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ABSTRACT
Background
Early administration of fibrinolytics after surgical treatment of peritonitis in the rat reduces abscess
formation. In clinical practice surgical treatment can be delayed for several reasons and there is 
concern about side effects of post-operative administration of  fibrinolytics. The current study 
investigates the effect of delayed and prolonged treatment with intraperitoneal recombinant tissue
plasminogen activator (rtPA) and the effect of lowering the dose of rtPA.
Study Design
Peritonitis was induced via intra-abdominal injection of a feces/bacteria mixture in male Wistar rats.
Surgical debridement was performed after 1h. In the first experiment four groups of animals were 
treated with 1.25 mg of rtPA starting at different time points, one group receiving prolonged treatment.
In a second experiment two groups were treated with either 0.25 mg or 1.25 mg of rtPA. Abdominal
fluid samples were taken at 24, 72 and 120 h for IL-6, IL-10 and TNF-αmeasurements and cell counts.
After 5 days the abdomen was inspected for abscesses.
Results
Early administration of rtPA in both  doses significantly reduced the number of rats with abscesses
and the abscess load per rat as compared to untreated controls. Delayed treatment significantly 
reduced abscess load but not the incidence of abscesses. No adverse side effects were observed and
no meaningful differences in the local inflammatory response were found. RtPA was most effective
when applied early and continued for 72 h, although mortality increased after prolonged treatment. 
Conclusions
RtPA consistently reduces intra-abdominal abscess formation. Future clinical research is warranted
addressing the issues of dosage and the potential benefit of early and prolonged  administration of
rtPA.
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INTRODUCTION
Secondary peritonitis is a life threatening condition mostly occurring after disruption of the integrity
of the gastrointestinal tract(1). In the last 30 years, mortality rates have hardly improved despite 
important advancements in perioperative care, antibiotic treatment and surgical therapy(2-4). 
Recurrent or ongoing abdominal sepsis is recognized as a main determinant of outcome(5). Intra-
abdominal abscesses are an important source of abdominal infection and cannot always be treated
successfully by either surgical or percutaneous techniques(6;7). Prevention of abscess formation after
surgery for peritonitis therefore remains an essential target for research.
Since fibrin deposition is an intrinsic element in abscess formation it is logical to investigate the 
potential of fibrinolytic therapy in this respect. Indeed, earlier preclinical studies have indicated that
exogenous tissue-type plasminogen activator (tPA) may reduce intraperitoneal abscess formation
during generalized peritonitis, though at the cost of significant mortality(8;9). Recently, we have 
optimized a model which is suitable to study the mechanisms involved in, and prevention of, intra-
abdominal abscess formation after surgical treatment of generalized peritonitis(10). Further studies
have demonstrated that repeated intraperitoneal administration of human recombinant tPA (rtPA)
significantly reduces abscess formation without consistent serious side-effects(11;12). The model 
shares important, but not all, features with the clinical situation. For instance, contrary to clinical
practice, antibiotics were deliberately not given in order to selectively study the potential beneficial
effects of fibrinolytics. Also, rtPA treatment has been restricted to the first 24 hours after bacterial 
inoculation and surgical debridement. In the clinical setting, early administration of rtPA might not
always be feasible: the time between onset of disease and presentation of clinical symptoms can
vary, establishing the diagnosis can be delayed and hence the time of initiating adequate therapy will
vary(13). Therefore we have addressed the following questions related to the rtPA regimen chosen so
far: is prolonged treatment more effective than treatment during 24 hours and can delayed rtPA 
treatment still be effective in reducing abscess formation? Anticipating the need to maximally reduce
the treatment-related risk profile, the efficacy of lowering the dose was also investigated.  
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MATERIALS AND METHODS
Animals
Male Wistar rats weighing 250-280 g (Harlan BV, Horst, the Netherlands) were housed two per cage
and accustomed to laboratory conditions for five days before the start of the experiment. All animals
had free access to water and standard rodent chow throughout the entire experimental period (Hope
Farms, Woerden, the Netherlands). The clinical condition and weight of the rats were monitored daily.
The Animal Ethics Review Committee of the Radboud University Nijmegen approved the study.
Induction and treatment of peritonitis
Peritonitis was induced in all rats by intraperitoneal injection of 2 ml of a fecal suspension containing
104 cfu Bacteroides fragilis (strain 25285 from the American Type Culture Collection) and 105 cfu 
Escherichia coli (strain 25922 from the American Type Culture Collection), respectively(10).
One hour after inoculation surgical therapy was performed. The rats were anesthetized by inhalation
of a mixture of isoflurane-oxygen-nitrous oxide. The abdominal cavity was debrided including 
partial resection of macroscopic  polluted omentum and rinsed with 5 ml of sterile saline of 380C.
The abdomen was closed with a running suture of 4.0 Polyglactin 910 (Vicryl ®, Ethicon,  Amersfoort,
The Netherlands), the skin was closed with staples. Rats received 5 ml normal saline subcutaneously
for resuscitation.
Experiment 1
One hundred animals were randomly divided into five groups of 20 rats each. The first group (rtPA)
was treated with 1.25 mg of rtPA (Actilyse®, Boehringer Ingelheim, Germany) dissolved in 2.5 ml 
saline, which was left in the abdomen at the end of the laparotomy at 1 hour. Via percutaneous 
injection additional doses rtPA were given at 6 and 24 hours. The second group (rtPA-long) received
prolonged rtPA treatment: doses of rtPA were given at 1, 6, 24, 36, 48, 60 and 72 hours. The third group
(rtPA-24) received three doses of 1.25 mg rtPA in sterile saline from one day after bacterial inoculation,
at 24, 30 and 48 hours. In the fourth group (rtPA-48), rtPA treatment was delayed for 2 days and doses
were given at 48, 54 and 72 hours. Finally, the control group was treated with sterile saline at 1, 6 and
24 hours after the induction of peritonitis (also see table 1).
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After five days the surviving rats were killed by CO2 asphyxiation. The abdomen was inspected, with
particular attention to signs of generalized peritonitis, the number and location of abscesses and
signs of intra-abdominal bleeding. All fibrin-encased purulent collections were considered abscesses.
The abscess load was represented by an abscess score. To this end, all abscesses were classified semi-
quantitatively according to their diameter: < 1 mm: 1;  1 - 2 mm: 2 and  > 2 mm: 3 points. For each rat,
the sum of these points represented the abscess score. Generalized peritonitis was defined as the 
presence of either diffuse purulent abdominal fluid, diffuse redness and edema of the peritoneum
or diffuse fibrinous adhesions between intra-abdominal organs.
Experiment 2
Forty five rats were randomly divided into three groups of 15 rats each. Two groups were treated 
similar to the control and rtPA group described in the preceding experiment. In the third group (rtPA-
low) each dose of rtPA was lowered five-fold to 0.25 mg in 2.5 ml saline. Further procedures were as
described above.
Sample collection and analysis 
In all animals peritoneal fluid samples were collected under anesthesia, at 24 and 72 h after bacterial
inoculation. After removing two skin staples and one abdominal wall stitch to gain access, 5 ml of 
sterile saline of 380C was installed in the abdominal cavity. The abdomen was gently massaged and
at least 2 ml of fluid were withdrawn. The samples were centrifuged for 10 min at 750 x g and 
supernatants stored at -800 C until further analysis.
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rtPA-48
rtPA-24
rtPA-long
rtPA
1 12 24 36 48 60 72 h
Table 1. Treatment scheme, experiment 1. Duration of rtPA administration displayed as a horizontal line.
Levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10) were mea-
sured in peritoneal fluid by using commercially available ELISA kits (Endogen®, Pierce Biotechnology
Inc, Rockford IL, USA). According to the manufacturer, the sensitivities for the various assays were 
< 10 pg/ml for TNF-α, < 16 pg/ml for IL-6 and < 3 pg/ml for IL-10, respectively.
The cellular content of peritoneal fluid samples was assessed after dilution of the sediment with 
saline (to a concentration of 50.000 cells/ml) and staining with May-Grunwald Giemsa reagent. 
Statistics
Mortality rates were compared by log rank test. Since the main objective of this study was to esta-
blish the effect of the different treatments per se, the functional outcome parameters in each of the
four experimental groups were tested for significance in relation to the control group. To correct for
the fact that multiple comparisons were made, pair-wise comparisons were done with a two-tailed
Mann-Whitney test using a level of significance of 2α/k where k is the total number of pair wise
comparisons. For instance, comparison of the four experimental groups with the control group in 
experiment 1 yields a significant difference if p<0.025. Trend analysis for the parameters regarding 
abscess formation was performed using a Pearson chi square test and COX regression.
RESULTS
Experiment 1
Survival and clinical course
All rats became severely ill after inoculation, as characterized by lack of movement, pilo-erection and
anorexia. Body weight decreased during the first 24 h after inoculation and stabilized thereafter. The
changes in body weight during the experimental period were similar in all groups. The overall survi-
val rate was 68%. Twenty-three of the 32 rats that died prematurely did so within 48 h after inocula-
tion. Survival was lowest in the rtPA-long group: 45% vs 90% in the control group (p = 0.002). The
other survival rates did not differ significantly from the controls and were 60%, 75% and 70% in the
rtPA-, rtPA-24- and rtPA-48-groups, respectively. No bleeding complications were observed in rats that
either survived until the end of the study or that died prematurely. In all surviving rats two or more
signs of peritonitis were observed at post mortem examination. In 2 animals that died, massive fi-
brinous adhesions and purulent collections were observed in the abdomen. 
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Abscesses
Only when rtPA treatment was initiated immediately after surgical debridement, the percentage of
surviving animals with abscesses was significantly reduced, from 89% in the control group to 58% and
33% in the rtPA and rtPA-long groups, respectively (Figure 1A). All rtPA treatments reduced both the
number of abscesses per rat (Figure 1B) and the abscess score (Figure 1C). For both parameters, the 
median values in the rtPA, rtPA-long, rtPA-24 and rtPA-48 groups were significantly below those in the
control group.
Comparing the location of abscesses, significantly more rats with abscesses at the diaphragm and in
the left and right paracolic gutter were observed in the control group as compared to the rtPA-long
group. Significantly more abscesses in the  left paracolic gutter were found in controls as compared
to the rtPA group, p<0.05 (Table 2).
Cytokines
There were no differences between controls and any of the experimental groups. Values at 24 h are
not shown since treatment of some groups was started at that time point or later. Between 24 and
72 hours, levels of IL-6 and IL-10, but not TNF-α, decreased in all groups. At 72 hours (Figure 2) median
IL-10 levels in the rtpa-24 group were reduced by 50% in comparison with controls: this was the only
significant (p = 0.016) difference found between experimental and control groups.
n Diaphragm Left paracolic Right paracolic
Controls 18 12 14 10
rtPA 12 4 5* 4
rtPA-long 9 2* 1* 0*
rtPA-24 15 3 11** 5
rtPA-48 14 6 7 4
Table 2. Distribution of abscesses in experiment 1.
Each column displays the number of rats in each group with abscesses in one of the three locations, where abscess formation was observed most 
frequently. Some rats had abscesses at multiple locations. * p<0.05 (Chi-square test) vs controls. **p<0.05 vs RTPA-long
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Figure 1a, 1b, 1c. Abscess formation in experiment 1. 
Percentage of rats with abscesses (A), number of abscesses per rat (B) as
well as the total abscess score per rat (C) are given. In A, numbers within
bars give the actual number of (surviving) rats within each group with
abscesses. In B and C, data are depicted as medians with 25-75 percentiles
in boxes and 5-95 percentiles represented as vertical lines. *: p < 0.05 vs
untreated controls.
Figure 2. Cytokines in peritoneal fluid.
IL-6 (A) , IL-10 (B) and TNF-α (C) concentrations (pg/ml) in peritoneal fluid
collected at 72 h after inoculation. Data are depicted as medians with 25-
75 percentiles in boxes and 5-95 percentiles represented as vertical lines.
*: p < 0.05 vs untreated controls.
A
B
C
A
B
C
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Cells
The total cell numbers in peritoneal samples did not significantly differ between groups. The 
percentage of neutrophils declined significantly with time (from 79% at 24 h to 18 % at 120 h). 
Eosinophils and macrophages increased from 4 to 24% and from 16 to 45%, respectively, while 
lymphocyte counts remained relatively stable (Figure 3).
Experiment 2
Survival and clinical course
As in experiment 1 all rats showed signs of severe illness. Sixteen rats died prematurely, 10 within the
first 48 h. The overall survival rate was 64%. Survival rates were 60%, 87% and 47% for controls, rtPA-
low and rtPA groups, respectively, the difference between the latter two groups reaching significance
(p = 0.017). No bleeding complications were found. In all surviving rats two or more signs of perito-
nitis were observed. At autopsy an intraperitoneal hematoma was observed in 3 (all rtPA group) out
of 16 rats that died prematurely.
Abscesses
The percentage of surviving rats with abscesses was significantly (p = 0.03) reduced in both the 
rtPA and the rtPA-low groups (Figure 4A). The median (range) number of abscesses per rat was 
significantly (p<0.05) higher in controls than in both the rtPA and rtPA-low groups (Figure 4B). 
Cytokines and cells
Between 24 and 72 hours, levels of IL-6 and IL-10 decreased significantly in controls and rtPA groups
and TNF-α levels increased in the rtPA-low group.
At 24 h levels of IL-6 and IL-10 were significantly (p<0.05) lower in the rtPA-low group than in the
rtPA and control groups  while TNF-α levels showed no differences. At 72 h levels of cytokines did not
significantly differ between groups.
The total cell numbers in peritoneal samples were similar in all groups at all time points. Qualitative
changes were the same as in experiment 1 and there was no clear and sustained effect of rtPA. If any,
the increase in the percentage of eosinophils seemed somewhat stronger after rtPA treatment, but
only between 24 and 72 hours. 
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Figure 3. Differential cell counts in abdominal fluid. 
Samples were taken at 24, 72 and 120 h after inoculation. A: macrophages, B:
neutrophils, C: eosinophils, D: lymphocytes. Data on each cell type are ex-
pressed as mean percentage of the total cell count. : controls; : rtpPA; :
rtPA-long;    : rtPA-24;    : rtPA-48.*: p<0.05 for rtPA-24 vs untreated controls.
Figure 4a, 4b. Abscesses formation in experiment 2. 
Percentage of rats with abscesses (A) and number of abscesses per rat (B). 
In B data are depicted as medians with 25-75 percentiles in boxes and 
5-95 percentiles represented as vertical lines. *: p < 0.05 vs untreated 
controls.
A
B
C
D
A
B
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DISCUSSION
Intraperitoneal application of rtPA consistently reduces intra-abdominal abscess formation after 
(surgical) treatment of secondary peritonitis. The beneficial effects of rtPA are reflected not only by
reduction of the number of rats with abscesses, but also by the number of abscesses per rat. The latter
is still significantly reduced when intra-abdominal fibrinolytic treatment is delayed for 24 h, although
then the incidence of intra-abdominal abscesses is not affected. Reduction of the abscess load, ex-
pressed as the abscess score can even be achieved until  48 hours after onset of disease. 
In the current model the animals do not die from the abscesses. Presumably, mortality is caused by
systemic sepsis and multi organ failure which develop early. Generally speaking, infection models
are well known for their significant variations in the course of disease between experiments. In our
model, animals are very sick during the first 24 h and their survival may depend on conditions parti-
cular to each experiment, for instance, the particular batch of animals used or the batch of inoculum,
although obviously full efforts are made to standardize the latter. Such variance could explain the 
observed difference in mortality between the control groups from (the independent) experiments 
1 and 2.
One could comment on the fact that mortality in the rtPA treated rats tends to be higher than in the
controls. In the present model, this is accepted as a calculated risk. Activation of coagulation and 
formation of fibrin deposits as a result of inflammation are considered instrumental in containing 
inflammatory activity to the site of injury or infection. Bacteria caught in fibrin clots are released
much faster into the abdominal cavity when intra-abdominal fibrinolytics are given, provoking the
risk of bacteremia, sepsis and death. This experimental set up has been chosen deliberately, in order
to optimally study the specific potential of rtPA in preventing abscess formation. Therefore, morta-
lity is not a primary outcome parameter. Administration of systemic antibiotics in this experimental
model cancels the differences between rtPA treated rats and controls in this respect(14;15)Although
systemic antibiotics do decrease mortality, they do not prevent abscess formation(15;16). It should
be emphasized that antibiotics are vital in the treatment of patients with generalized peritonitis and
thus will always be part of therapy  in clinical practice.
The dose of 1.25 mg of rtPA for each gift has been chosen according to results in clinical studies on
thrombo-embolic diseases, taking into account that rat coagulatory activity is 2.7 times higher than
in humans(17). Applying a five-fold lower dose of rtPA is still effective in significantly reducing 
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abscess formation. One of the concerns of applying a fibrinolytic drug in peritonitis is the risk of 
bleeding complications. The chance of local bleeding complications is considered to be low in a rat
peritonitis model. This is explained by a decreased plasminogen activator activity (PAA), probably as
a result of elevated levels of plasminogen activator inhibitor (PAI)(18). Dose reduction may have no
clear advantage over the chosen dosing scheme under standardized conditions, but might be bene-
ficial in specific high-risk clinical cases. For instance, in patients suffering ongoing low-grade abdo-
minal sepsis who are at risk of developing recurrent abscesses(19). In these patients prolonged
fibrinolytic therapy in a low dose may reduce the need for surgical (re)intervention for abscesses.
This is of clinical importance for surgical reintervention itself bears a 22-77% mortality rate(20). 
In the current study prolonged treatment with rtPA tends to yield the best results with respect to 
abscess reduction, yet at the expense of significantly higher mortality as compared to controls. 
Therefore, if prolonged application of rtPA would seem advantageous, particular attention should
be paid to dosage. 
Until now the results of our preceding studies revealed no adverse effects of rtPA(11;12), if treatment
was given as in the current rtPA groups.  The increased mortality rate after prolonged treatment, as
observed in experiment 1, cannot be explained in terms of bleeding complications or an altered local
inflammatory response. The number of bleeding complications in the group that received prolonged
treatment was nil. Although an immune modulatory effect of rtPA has been suggested recently(21),
neither significant difference in the intraperitoneal cellular response, nor differences in local cytokine
expression during the first 72 hours after inoculation were observed. Both cellular and cytokine 
response are most pronounced during the first 48 to 72 hours after the  onset of peritonitis(22;23). 
Presumably, increased mortality is a logical consequence of premature release of bacteria into the 
abdominal cavity (see above) and not related to interference of rtPA with the immunological defense
mechanisms in the abdominal cavity.
When interpreting the results of the current study one should realize that peritonitis was induced in
a standardized way and was treated at a fixed time point. The finding that rtPA still seems to be 
effective in terms of abscess reduction if started 24 h, and possibly even 48 h after bacterial inocu-
lation is of particular interest. In the clinical setting, abdominal sepsis may present itself in different
ways and it is known for its broad variety in causes and severity of the infection(24;25). Patient’s as
well as doctor’s delay account for variations in the timing of adequate therapy(26). Immediate 
application of fibrinolytics at the end of the operation in patients with intra-abdominal sepsis seems
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to be the most logical strategy to prevent intra-abdominal abscess formation.
Altogether, these results point out the potential benefits of applying rtPA as an adjunct to the standard
treatment of peritonitis in the clinical setting. Obviously, safe rtPA dosages, possibly derived from
those used in for instance thrombo-embolic diseases(27;28), should be tested in a phase II study. 
Bearing in mind that frequently the clinical course will be protracted requiring peritonitis patients to
receive supportive treatment for a longer period, the effects of prolonged treatment with a low dose
of rtPA should be investigated.  
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Chapter 6
Plasminogen activator, but not systemic 
antibiotic therapy, prevents abscess for-
mation in secondary peritonitis in the rat
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ABSTRACT
Background
Intra-abdominal abscesses are sources for recurrent or ongoing abdominal sepsis. They constitute
an important target for prevention or treatment after surgery for peritonitis. Prior experimental data
suggest intraperitoneal fibrinolytic therapy to be effective and feasible, but this was only established
in the absence of antibiotics
Method
Peritonitis was induced via intra-abdominal injection of a faces/bacteria mixture in rats. Surgical 
debridement was performed after 1 h. Animals were treated with antibiotics (ceftriaxone plus 
metronidazole for 3 days), recombinant tissue plasminogen activator (rtPA for 1 day) or both. Abdo-
minal fluid samples were taken at 24, 72 and 120h for cytokine measurements and cell counts. After
5 days the abdomen was inspected for the presence of abscesses.
Results
Antibiotics did not significantly affect abscess formation (median number 4.5 in controls). RtPA 
significantly reduced the number of rats with abscesses and the abscess load per rat, both in absence
and presence of antibiotic therapy (median number 0 in both rtPA groups). No adverse side effects
were observed and no meaningful differences in the local inflammatory response were found.
Conclusion
rtPA consistently reduces abscess formation in a model for the surgical treatment of secondary 
peritonitis in the rat: it thus represents a promising adjuvant to conventional therapy.
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INTRODUCTION
Sepsis and the systemic inflammatory response syndrome are the most common causes of death in
adult intensive care units(1;2). Intra-abdominal infection is a well-known cause of severe sepsis and
remains associated with a significant morbidity and mortality(3). In secondary peritonitis the 
gastrointestinal barrier is disrupted which leads to intra-abdominal infection caused by microbial 
pathogens or their products(4). Treatment is based on three modalities: surgery, antibiotic treatment
and restoration and preservation of organ perfusion and oxygenation. Although improvements have
been made over the years in all three, mortality and morbidity rates have hardly improved(5). 
Despite adequate treatment residual or recurrent infection is relatively frequent, necessitating a 
relaparotomy in 42% of all cases(6).
Intra-abdominal abscesses are well-known sources for recurrent or ongoing abdominal sepsis and
therefore constitute an important target for prevention or elimination(7). During peritonitis both
intra-abdominal coagulation and fibrinolysis are up-regulated to a different degree, resulting in a
net increase of coagulation activity(8-10). As a consequence, fibrin deposits will form that serve to 
sequestrate the source of infection but also constitute a nidus of intra-abdominal abscesses.
In order to prevent abscess formation, attempts were made to enhance fibrinolytic activity with 
recombinant tissue-type plasminogen activator (rtPA) in rats with generalized peritonitis(11;12). While
a significant reduction of abscess formation was observed, this was only achieved at the cost of 
increased mortality. The latter could be largely prevented by a single high dose of potentially nephro-
toxic gentamycin(13). More recently, ‘proof of principle’ was supplied that such a beneficial effect of
rtPA, if administered differently, is possible without adverse side effects(14). These experiments were
performed in the absence of systemic antibiotics. Clinically the essential role of antibiotic therapy as
an adjunct to surgical treatment of peritonitis is firmly established(15). Therefore in the current study,
the effect of clinically relevant systemic antibiotics, delivered in the first days after surgical therapy
of induced peritonitis, on intra-abdominal abscess formation have been investigated in the rat. These
experiments were conducted both in the absence and presence of intraperitoneally applied rtPA.
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MATERIALS AND METHODS
Experimental design
Seventy-two animals were randomly divided into four equal groups. Peritonitis was induced by 
intraperitoneal injection of 2 ml of a fecal suspension containing 104 cfu B. fragilis (strain 25285 from
the American Type Culture Collection) and 105 cfu E. coli (strain 25922 from the American Type Culture
Collection), respectively(16). One hour after inoculation, the rats were anesthetized by inhalation of
a mixture of isoflurane-oxygen-nitrous oxide. The abdominal cavity was debrided including partial
omentectomy and rinsed with 5 ml of sterile saline of 380C. The abdomen was closed with a running
suture of 4.0 Polyglactin 910 (Vicryl®, Ethicon, Amersfoort, The Netherlands), the skin was closed with
staples. Rats received 5 ml normal saline subcutaneously for resuscitation. 
The first (control) group received no further drug treatment, the second group (rtPA) received rtPA
intra-abdominally, the third group systemic antibiotics (AB) and the fourth group antibiotics 
plus rtPA (rtPA+AB group). Human rtPA (1.25 mg in 2.5 ml saline,  Actilyse®, Boehringer Ingelheim, 
Germany) was given as an intraperitoneal bolus, once at the end of surgery and then, percutanously,
at 6 and 24 hours after inducing peritonitis. The groups that did not receive rtPA were treated with
saline at the same time points.
Antibiotic therapy was given for the first three days and consisted of 15 mg/kg Metronidazole (Aven-
tis Pharma B.V. Hoevelaken, The Netherlands), twice daily subcutaneously, and 15 mg/kg Ceftriaxone
(Roche Nederland B.V.  Mijdrecht, The Netherlands), twice daily intramuscularly. After five days the
surviving rats were killed, a laparotomy was performed and the abdomen was inspected. Particular
attention was paid to number and location of abscesses as well as to signs of intra-abdominal 
bleeding. The location of abscesses was divided into diaphragmatic, right and left paracolic area. 
All fibrin-encased purulent collections were considered to represent abscesses. All abscesses were
scored semi quantitatively according to their diameter: < 1 mm: 1;  1 - 2 mm: 2 and  > 2 mm: 3. For each
rat, the total number represented the abscess score. Generalized peritonitis was defined as the 
presence of either diffuse purulent abdominal fluid, diffuse redness and oedema of the peritoneum
or diffuse fibrinous adhesion between intra-abdominal organs.
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Animals
Male Wistar rats weighing 250-280 g (Harlan BV, Horst, the Netherlands) were housed two per cage
and accustomed to laboratory conditions for five days before the start of the experiment. All animals
were weighed daily and had free access to water and standard rodent chow throughout the entire
experimental period (Hope Farms, Woerden, the Netherlands). The Animal Ethics Review Committee
of the Radboud University Nijmegen approved the study
Sample collection
At 24 h after inducing peritonitis, 500 microliter blood samples were taken for culture by orbital
plexus puncture under general anaesthesia. Samples were collected in sterile tubes containing 50 IU
of heparin. 
Peritoneal fluid samples were collected under general anaesthesia at 24, 72 and 120 h after bacterial
inoculation. After reopening the abdomen, 5 ml of sterile saline of 380C was installed in the abdominal
cavity. The abdomen was gently massaged and at least 2 ml of fluid were withdrawn. The samples
were centrifuged for 10 min at 750 x g and supernatants stored at -800C until further analysis. 
Sample analysis
Heparinised blood samples (300 µl) were cultured for the presence of E. coli. Serial dilutions in Brain
Heart Infusion broth were plated onto MacConkey blood agar plates. After 48 h of incubation at 370C
bacteria were identified and counted. 
Cells were counted in the samples of peritoneal fluid after dilution of the sediment with saline to a
concentration of 50.000 cells/ml and staining with May-Grunwald Giemsa reagent. Levels of tumour
necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10) were measured in peritoneal
fluid at 24 and 72 h. All assays were performed using commercially available ELISA kits (Endogen®,
Pierce Biotechnology Inc, Rockford IL, USA). According to the manufacturer, the sensitivities for the 
various assays were < 10 pg/ml for TNF-α, < 16 pg/ml for IL-6 and <3 pg/ml for IL-10, respectively.
Statistics
Statistical analysis was performed using two-way Kruskal-Wallis test followed by Dunn’s multiple
comparison test and Mann Whitney test. Trend analysis for the abscess related parameters was per-
formed using a Pearson chi square test and COX regression. P values < 0.05 were considered significant.
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RESULTS
Clinical course and survival 
All rats became ill after inoculation, as characterized by lack of movement, pilo-erection and ano-
rexia. Body weight decreased consistently and significantly (p<0.05) and stabilized at the 4th day. At
this time, average weight loss in the control group was 9.3 %. The changes in body weight during
the experimental period were similar in all groups. One rat in the rtPA group died at day 2. Generalized
peritonitis was apparent on post mortem examination. No bleeding complications were observed.
Abscesses
Intra-abdominal abscesses were found in 15 out of 18 rats in the control group and in 17 out of 18 in
the group treated with antibiotics alone. Systemic antibiotics alone did not reduce the number of rats
with abscesses, while rtPA did, also in the presence of antibiotics (Figure 1). Similar results were 
obtained for the number of abscesses per rat (Figure 2A) and the abscess score (Figure 2B), which
showed the same pattern and significant differences between groups. 
Overall, abscesses were found at preferential locations, i.e. in the sub diaphragmatic area and in the
paracolic gutters. In particular, significantly more rats with abscesses at the diaphragm and the left
paracolic gutter were observed in controls as well as in the AB group as compared to the rtPA and
rtPA+AB groups. In addition, significantly more rats with abscesses at the right paracolic gutter were
observed in the controls as compared to the rtPA group (Fisher exact test p<0.01, table 1). When 
comparing total numbers of abscesses at the preferential locations similar results were found.
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Figure 1. Percentage of rats with abscesses. 
The numbers within the columns indicate the actual number of rats with abscesses
(represented as black bars) versus the total number of survivors in that group. 
*indicates a significant (p<0.001, chi-square) difference with the rtPA-treated groups.
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Figure 2a en 2b. Abscess data. Both the number of abscesses per rat (A) and the abscess score (B) are depicted. Data are represented as medians (measurements
in all surviving animals) with 25-75 percentiles in boxes and 5-95 percentiles represented as vertical lines. *indicates a significant (p<0.001, Kruskal-Wallis
plus Dunn’s test) difference with the rtPA-treated groups.
n Diaphragm Right paracolic Left paracolic
Controls 18 22* 7** 44*
rtPA 17 0 0 5
Antibiotics 18 13* 12** 28*
rtPA + antibiotics 18 0 3 6
Table 1b. Distribution of abscesses. Total number of abscesses at preferential locations.
*significantly (p<0.05) more abscesses as compared to rtPA and rtPA + antibiotics. **significantly (p<0.05) more abscesses as compared to rtPA.
n Diaphragm Right paracolic Left paracolic
Controls 18 12* 6** 15*
rtPA 17 0 0 4
Antibiotics 18 8* 9** 12*
rtPA + antibiotics 18 0 3 3
Table 1a. Distribution of abscesses. Number of rats with abscesses at preferential locations.
*significantly (p<0.05) more abscesses as compared to rtPA and rtPA + antibiotics. **significantly (p<0.05) more abscesses as compared to rtPA.
A B
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Blood cultures 
Positive blood cultures were found in 11-44% of all rats. The median number (range) of colony forming
units per rat varied from 20 (20-100) cfu/ml to 220 (20-1200) cfu/ml. There were no significant 
differences between the groups with respect to either the number of rats with positive cultures or
the mean number of colony forming units per group. 
Cytokines
The levels of IL-6 and IL-10 significantly declined in all groups from 24 h to 72 h, while levels of TNF-α
significantly increased over this period (Figure 3).
IL-6 levels at 24 h were significantly higher in the rtPA group than in the rtPA+AB group (p < 0.01). 
At 72 h IL-6 levels did not significantly differ between groups. Levels of TNF-α and IL-10 did not 
significantly differ between groups at either 24 or at 72 h.
Cells
At all time points the total cell numbers in peritoneal samples did not significantly differ between
groups. In the controls, the percentage of neutrophils declined with time (from 77% at 24 h to 19% at
120 h). Eosinophils and macrophages increased, from 6 to 42% and from 17 to 32%, respectively. 
Treatment with antibiotics did not affect these numbers. In general, treatment with rtPA did result
in lower percentages of neutrophils and higher percentages of eosinophils, although differences
were relatively small and only significant by exception.
DISCUSSION
Intra-abdominal abscess formation after surgical treatment of generalized peritonitis in rats can be
reduced by intraperitoneal application of rtPA, but not by antibiotics. Neither rtPA nor antibiotics, 
administered either alone or in combination, influence mortality or alter the inflammatory response
in the abdominal cavity.
The present study is one out of a recent series of sequential experiments in rats with generalized 
peritonitis. Until now, systemic antibiotics were deliberately not applied in order to study potential
effects of interventions step by step. Intraperitoneal applied fibrinolytic therapy with rtPA or urokinase
was shown to be effective in preventing intra-abdominal abscess formation in rats with generalized
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Figure 3. Cytokines in abdominal fluid. Data for IL-6 (A,B), TNF-α (C,D) and IL-10 (E,F) are depicted as means (measurements in all surviving animals) plus SEM
represented as vertical lines. * indicates a significant (p<0.01, Kruskal-Wallis plus Dunn’s test) difference between groups. † indicates a significant difference
for cytokine levels at 24 versus 72 h. 
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peritonitis(14;17). Three doses of rtPA, given over 24 hours, were more effective than either a single or
two consecutive doses in preventing abscess formation(14). RtPA is the main activator of plasmin,
which in turn is the key enzyme in fibrin degradation(18) and can thus act to break down abscess
walls that are mainly composed of fibrin(19). The latter is formed as a result of the physiologic reaction
to any kind of trauma to the peritoneum, e.g. peritonitis. After peritoneal trauma, a fibrin matrix 
develops which acts as a scaffold for repair cells to migrate and exert their functions. The fibrinolytic
system removes the fibrin in order to establish physiologic, adhesion-free healing(20). 
The present experiment confirms recent studies on the effects of rtPA alone. The current rtPA dose
is based on its clinical use for treatment of thrombo-embolic disorders(21), considering that the 
coagulation activity rate in the rat is elevated by a factor 2.7 compared to man(22).  Abscess reduction
by application of rtPA was reflected not only in the percentage of rats without abscesses or the 
median number of abscesses per rat. The distribution of abscesses changed as well. In the rtPA 
treated groups significantly fewer abscesses were found in the paracolic gutter and the sub-dia-
phragmatic spaces. This is explained by the cephalad peritoneal fluid stream transporting rtPA from
the abdominal cavity via the paracolic gutters to the sub-diaphragmatic spaces(23).  
Improvements of outcome of peritonitis have so far been achieved by subduing the systemic effects
of abdominal sepsis. Timely delivery of adequate antibiotic therapy is of paramount importance for
survival in the clinical setting(15). Data on strategies to improve control of the local infection and 
inflammation remain equivocal(6;15;24-26).The combination of metronidazole and ceftriaxone is
known to be effective in the treatment of secondary peritonitis in humans(27;28). In animal models
this antibiotic regimen induced an improvement of survival(29;30). In the current study mortality
was only 1.3%, precluding any conclusions with respect to the possible effect of systemic antibiotic
therapy on survival. The current study shows that systemic antibiotic therapy has no effect on abscess
formation. This may have two causes. First, fibrin renders bacteria unreachable for antibiotics and
the immune system in the abdominal cavity. Second, antibiotics may be less effective due to the low
pH, protein binding and degradation by bacterial enzymes in abscesses(31).
Inflammatory cytokines and cell counts were studied in addition to abscess formation in order to
detect a possible effect explaining the action mechanism of rtPA whether or not in combination with
antibiotics. RtPA may have an immune modulatory effect in the abdominal cavity, although the 
precise mechanism is not understood(32;33). The available data on the influence of rtPA on the local
inflammatory response in peritonitis are mainly experimental and open to multiple interpretations.
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Endogenous tPA deletion or targeting in mice leads to impairment of the inflammatory response to
E. coli peritonitis. In tPA-/- mice similar peritoneal neutrophil counts but higher local bacterial loads
and higher levels of neutrophil attracting chemokines were found, if compared to wild type mice(32).
These results suggest a reduced migratory response. Intra-abdominal application of exogenous tPA
in a caecal ligation and puncture model reduced bacterial load and leukocyte influx. However, the 
effects on cytokine response were equivocal(34). Cook et al. showed that the number of macrophages
in peritoneal exudate was reduced in experimental peritonitis, but could be increased by applying 
exogenous tPa or plasmin(35). Altogether, at this point, the implications for the clinical setting from
the above mentioned results remain unclear.
In the current study equivocal observations regarding alteration of the local inflammatory response
were made. At 24 h a significantly higher level of pro inflammatory IL-6 was measured in the rtPA 
treated group as compared to the rtAP+AB group. Apparently, the addition of antibiotics to rtPA 
reduced the pro-inflammatory effect of rtPA, although there was no difference between the rtPA
group and the controls. A similar finding was observed with respect to TNF-α levels at 24 h. No effect
on levels of anti-inflammatory IL-10 was observed. In the existing literature there are no data on the
possible interaction of rtPA and antibiotics, as used in the present study, with respect to inflammatory
response. Regarding the cellular response, significant differences were observed only between 
controls and the rtPA group. Yet, these findings were ambiguous because they involved a different 
cell type at each time point. The addition of antibiotics to rtPA treatment did not affect the cellular
response.
It is concluded that intra-abdominal application of rtPA consistently reduces abscess formation and
therefore is a promising adjuvant to systemic antibiotics in the therapy of secondary peritonitis.
It should be noted that for clinical practice the necessity for repeat dosing might require the standard
use of an indwelling device. Antibiotic treatment alone does not contribute significantly to reduction
of abscess formation but is important in reducing the systemic effects of peritonitis. These results
further corroborate the potential role of fibrinolytic therapy in optimal treatment of secondary 
peritonitis and support advancement into a phase two clinical trial. 
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Chapter 7
Tissue-type plasminogen activator prevents
abscess formation but does not affect hea-
ling of bowel anastomoses and laparotomy
wounds in rats with secondary peritonitis
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ABSTRACT
Background
Intra-abdominal application of recombinant tissue-type plasminogen activator (rtPA)  can decrease
the rate of abscess formation in a rat peritonitis model. Before using rtPA clinically, its effects on 
healing of bowel anastomoses and laparotomy wounds should be investigated.
Methods
Peritonitis was induced in 148 male Wistar rats via intra-abdominal injection of a feces/bacteria mix-
ture. Laparotomy, operative debridement and construction of a colo-colostomy after a limited colec-
tomy or ileo-ileostomy after a limited ileal resection were performed after 1 h. All animals received
antibiotics (ceftriaxone plus metronidazole). In addition to untreated controls, other animals received
rtPA in either of three dosing schemes, starting immediately after operation or 24 h afterwards.
Wound strength and hydroxyproline content of the wound were analyzed after 3 or 7 days. 
Results
Mortality was 2% and manifestations of excessive bleeding were virtually absent. RtPA significantly
decreased the rate of abscess formation. Neither bursting pressure nor breaking strength of the 
anastomoses was affected by any of the rtPA protocols. The same was true for wound strength in the
abdominal fascia. Also, wound hydroxyproline content and wound architecture remained unchanged
after rtPA administration.
Conclusion
Intraperitoneal rtPA administration consistently and significantly decreased the rate of abscess 
formation but did not affect wound healing. Clinical studies investigating its potential as an adjunct
in the treatment of secondary peritonitis may be warranted.
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INTRODUCTION
Secondary peritonitis is a life-threatening disease that is caused usually by perforation of the digestive
tract(1). The therapy of secondary peritonitis is based on surgical source control, resuscitation, and 
systemic antibiotic therapy(2;3). Surgical therapy often involves laparotomy and bowel resection. Con-
structing an intestinal anastomosis is justified in selected patients(4;5). Despite optimal treatment,
intra-abdominal abscesses occur in 15-25% of patients and can lead to ongoing and recurrent abdo-
minal sepsis(6;7). 
During peritonitis both intra-abdominal coagulation and fibrinolysis are up-regulated to a different 
degree, resulting in a net increase of coagulation activity and deposition of fibrin. These fibrin deposits
contain viable bacteria that become unreachable for the local immune defenses in the abdominal 
cavity and for antibiotics and thus form the nidus for intra-abdominal abscesses(8;9). Fibrinolytic 
therapy may offer an attractive way to reduce the risk of abscess formation.
Recently, we reported new preclinical evidence that treatment with recombinant tissue-type plasmi-
nogen activator (rtPA) after operative debridement for secondary peritonitis may prevent abscess for-
mation without unwanted side-effects(10;11). Before initiating a clinical study, it becomes necessary to
ascertain that rtPA treatment does not interfere with the healing of abdominal wall fascia or bowel
anastomoses, which would increase the risk of burst abdomen or anastomotic dehiscence. 
Fibrin deposition is intrinsic to early wound repair and provides a provisional scaffold for ingrowth of
fibrocollagenous tissue and for cell migration. An excessive presence of fibrinolytic factors such as
rtPA may induce premature degradation of this provisional matrix. In addition, the plasminogen acti-
vator/plasmin system can activate the matrix metalloproteinases, which are already induced during
wound repair(12). Both processes could thus result in unwanted matrix degradation, decrease in the
suture-holding capacity, and ultimately result in decreased wound strength. There are few data on the
effects of exogenous rtPA on wound healing, although a detrimental effect has been suggested(13).
We designed a comprehensive experiment to study the effect of the intraperitoneal application of
rtPA on healing of bowel anastomoses and abdominal wall fascia after operative debridement of se-
condary peritonitis in the rat. We have previously validated the therapeutic dosage scheme of rtPA in
decreasing the rate of abscess formation(10;14).
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MATERIALS AND METHODS
Design of the study
Male Wistar rats weighing 250-280 g (Harlan BV, Horst, the Netherlands) were housed two per cage
and accustomed to laboratory conditions for five days before the start of the experiment. Peritonitis
was induced in all rats, and 1 h later, operative debridement was performed. Therafter, animals under-
went resection and anastomosis in either colon or ileum. Intraperitoneal rtPA treatment consisted of
3 doses administered over a 24 h period. The first dose was given either immediately after operation
or 1 day later. Animals were killed 3 or 7 days after operation. All animals were weighed daily and had
free access to water and standard rodent chow throughout the entire experimental period (Hope
Farms, Woerden, the Netherlands). The Animal Ethics Review Committee of the Radboud University 
Nijmegen approved the study.
Induction and treatment of peritonitis
Peritonitis was induced in all rats by a transcutaneous, intraperitoneal injection of 2 ml of a fecal 
suspension containing 104 colony forming units (cfu) of Bacteroides fragilis (strain 25285 from the
American Type Culture Collection) and 105 cfu of Escherichia coli (strain 25922 from the American Type
Culture Collection), respectively(15)., One h after inoculation, operative therapy was performed. The
rats were anesthetized by inhalation of a mixture of isoflurane (Abbott Laboratories, Queensborough,
UK) -oxygen-nitrous oxide. The abdominal cavity was debrided including partial resection of the omen-
tum: all dead or macroscopically infected tissue as well as any contaminated material was removed and
the abdominal cavity was irrigated with 5 ml of sterile 0.9% NaCl of 380C. Antibiotic therapy was given
for the first three days and consisted of 15 mg/kg metronidazol (Aventis Pharma B.V. Hoevelaken, The
Netherlands), twice daily subcutaneously, and 15 mg/kg ceftriaxone (Roche Nederland B.V.  Mijdrecht,
The Netherlands), twice daily intramuscularly.
Study groups
In the first experiment, colonic resection and anastomosis were performed in 120 rats immediately
after debridement of the abdominal cavity. The animals were randomized into four groups of 30 rats.
In the first group (rtPA), human rtPA (Actilyse®, Boehringer Ingelheim, Germany), in a dose of 1.25 mg
in 2.5 ml of 0.9% NaCl, was given as an intraperitoneal bolus, once at the end of the operation and
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then, percutanously, at 6 and 24 h after bacterial inoculation. The second group (rtPA-low) was treated
identically but each rtPA dose was 0.25 mg. In the third group (rtPA-del), three intraperitoneal doses
of 1.25 mg rtPA were given at 24, 30 and 48 h after bacterial inoculation. The control group was similar
to the rtPA group but received intraperitoneal 0.9% NaCl only. Within each group, half of the animals
(15 in each group) were killed at 3 and 7 days after operation, respectively. Twelve animals were used
for assay of wound strength and the remaining for histology.
In the second experiment, ileal resection and anastomosis was performed in 28 rats immediately after
debridement of the abdominal cavity. The animals were randomized into two groups of 14 rats. The first
group received 1.25 mg of rtPA intraperitoneally after operation and,6 and 24 h after bacterial inocu-
lation. The second group received intraperitoneal 0.9% NaCl only at the same time points. All rats were
killed at the third postoperative day and used for determination of wound strength.
Bowel anastomoses
Procedures were performed under semi sterile conditions using a Zeiss operation microscope (Carl
Zeiss AG, Oberkochen, Germany). In experiment 1, a 2 cm resection of the descending colon, 3 cm proximal
to the peritoneal reflection was performed. Colonic continuity was restored by constructing an end-
to-end anastomosis with 8 single-layer, inverting, interrupted sutures (Ethilon 8-0, Ethicon, Germany).
In experiment 2, a similar resection and end-to-end anastomosis was performed in the distal ileum,
15 cm proximal to the cecum. During operations, body temperature was kept at 38°C using a heating
pad and a lamp. Animals were monitored by means of pulse oximetry and temperature measuring
devices. Intestines were covered with gauze pads soaked with 0.9% NaCl to minimize desiccation. 
To prevent dehydration, 5 mL of 0.9% NaCl was administered subcutaneously during the operation. 
Perioperative analgesia was given with buprenorphine, 0.02 mg/kg subcutaneously, twice daily for 2
days. Animals were weighed daily. All operative procedures were performed by the same investigator.
Analysis of abscess formation and wound strength
Rats were killed by CO/CO2 asphyxiation at either the third or the seventh postoperative day, and the
abdomen was inspected. Particular attention was paid to the number of abscesses and to signs of
intra-abdominal bleeding. All fibrin-encased purulent collections were considered to represent 
abscesses, which were scored semi-quantitatively according to their diameter: < 1 mm: 1 point;  1 - 2 mm:
2 points and  > 2 mm: 3 points. For each rat, the sum of these points represented the abscess score. 
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Generalized peritonitis was defined as the presence of either diffuse purulent abdominal fluid, diffuse
redness and edema of the peritoneum, or diffuse fibrinous adhesion between intra-abdominal organs.
Adhesions were dissected carefully without manipulation of the anastomosis. Presence of adhesions
or anastomotic dehiscence was recorded. Segments containing the anastomoses were resected. 
To measure bursting pressure, the segments were infused (2 mL/min) with 0.9% NaCl containing 
methylene blue. The maximum pressure (mm Hg) recorded immediately before sudden loss of pres-
sure was taken as the bursting pressure. The site of rupture (within or outside the anastomotic line)
was noted. Subsequently, the segments were placed in a tensiometer, and the breaking strength
(grams) was measured(16;17). To determine the abdominal wall strength, two full-thickness strips of 3
to 7 mm width and  20 mm length were cut from the abdominal wall between sutures. Breaking
strength in these samples, containing fascia and muscle layer, was measured longitudinally in a 
tensiometer and expressed as gram/mm.
Biochemical analysis and histology
After measuring wound strength, the tissue samples were dissected from adhering tissue and debris,
and 5 mm samples containing the anastomosis or the abdominal suture line of the midline fascia
were frozen in liquid nitrogen and stored at -800C until further processing. After lyophilization, tissue
samples were weighed, pulverized, and lyophilized again. The hydroxyproline content, as a measure of
the collagen content, was measured by high-performance liquid chromatography after hydrolysis with
6 N HCL acid and derivatization with dabsyl-chloride(18). 
Sections of anastomoses and abdominal wall originating from separate animals that had not been sub-
jected to strength measurements were washed in 0.9% NaCl, spread out, and fixed immediately in a 4%
phosphate-buffered formaldehyde solution. Subsequently, the samples were dehydrated and embedded
in paraffin blocks. Sections of 4 µm in thickness were stained with hematoxylin and eosin (H&E).
Statistics
The differences in rate of abscess formation between the control group and each of the experimental
groups were tested using a Mann-Whitney test and employing a Bonferroni correction.  Differences in
wound strength and hydroxyproline content were analysed with a Kruskal-Wallis test with a Dunn
correction for multiple comparison. All tests were two-sided; the level of significance was set at p < 0.05.
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RESULTS
Experiment 1: colonic anastomoses
Clinical course and abscess formation: All rats became severely ill after inoculation, as characterized by
lack of movement, pilo-erection, and anorexia. Body weight decreased during the first 4-5 days after
operation and stabilized thereafter. The changes in body weight during the experimental period were
similar in all groups (Figure 1). Overall survival rate was 117/120 (98%). No significant differences in 
survival between groups were observed. In one rat of the rtPA group that died prematurely, a subcu-
taneous hematoma and a small amount of intra-abdominal blood was found. No abnormalities were
found in the two other rats that died prematurely, one from the rtPA group and one from the rtPA-del
group. No signs of bleeding were observed in rats that survived until the end of the study. In all survi-
ving rats, two or more signs of peritonitis were observed at post mortem examination. 
Treatment with rtPA decreased the rate of abscess formation. At day 3, both the number of abscesses
per rat and the abscess score were less in all the treatment groups when compared to the control
group (p<0.05; figure 2). The number of rats without abscesses increased from 0/15 in the controls to
7/14, 5/15 and 1/15 in the rtPA, rtPA-low, and rtPA-del groups, respectively. On day 7, similar results were
found (data not shown), with both abscess numbers and abscess score being less in the rtPA and rtPA-
low groups than in the controls (p<0.05). No wound infections were observed.
Wound strength: In all groups, both anastomotic and fascial wound strength significantly  increased
from 3 to 7 days after operation (p<0.05). The increase in anastomotic breaking strength was similar
in all groups (Figure 3A) and at neither time point was a difference between controls and rtPA-treated
groups observed. The same was true for the anastomotic bursting pressure in the colon. At day 3, the
bursting site was almost invariably within the suture line, while at day 7, bursting occurred usually
outside the anastomosis in the adjacent tissue (Figure 4).
The breaking strength of the fascial wounds was very low after 3 days and increased rapidly there-
after (Figure 3B). Again, none of the rtPA treatment protocols resulted in measurable changes in
wound strength.
Hydroxyproline content and histology: Neither hydroxyproline concentration nor hydroxyproline 
content at day 7 differed between groups, for either the colonic or fascial wounds (Table 1). While
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Figure 1. Changes of body weight.
Average weight is expressed as percentage of weight at the time of bac-
terial inoculation.     Controls,     rtPA,     rtPA-low,     rtPA-del
Figure 2. Abscess formation. Number of abscesses per rat (A) and the total
abscess score per rat (B) after 3 days. Controls and rtPA-low: n = 15; rtPA and
rtPA-del: n = 14. Data are depicted as medians with 5-95 percentiles in boxes
and range represented as vertical lines. *: p < 0.05 vs untreated controls.
Figure 3a, 3b. Wound breaking strength.
Anastomotic (A) and fascial (B) breaking strength (B) at day 3 and day 7. Data are depicted as mean + standard error of mean (n=12). 
A B
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comparison of the anastomotic hydroxyproline content indicated an overall difference between
groups (p=0.033, Kruskal-Wallis), the (Dunn’s) post test failed to demonstrate actual differences 
between the control group and any of the experimental groups. 
A comprehensive examination of sections obtained from each group failed to reveal any obvious 
architectural differences between the groups at day 3 or at day 7. Semi-quantitative analysis also 
failed to indicate any differences between control and rtPA-treated groups with respect to histologic
parameters such as epithelial damage, wound area surface, degree of necrosis, edema, mucosal 
repair, and cellular infiltration. 
These findings are illustrated in figure 5, which gives typical examples of H/E sections of anastomoses
in the colon from controls and animals from the rtPA group at day 3 and day 7 after operation.
Figure 4. Anastomotic bursting pressure. Individual values for colonic anastomoses at day 3 (A) and day 7 (B). The vertical lines represent median values.
bursting site within the anastomosis,   bursting outside the suture line. 
Hydroxyproline concentration Hydroxyproline content
Colon Fascia Colon Fascia
Controls 12.5 ± 2.1 24.9 ± 7 307 ± 56 95 ± 28
rtPA 11.4 ± 1.5 20.8 ± 5.7 251 ± 46 88 ± 17
rtPA-low 12.4 ± 2.6 25.8 ± 8.4 254 ± 52 91 ± 25
rtPA-del 13.4 ± 1.7 25.0 v 8.4 299 ± 66 99 ± 32
Table 1. Hydroxyproline levels in colonic anastomotic tissue and fascia of the abdominal wall on day 7 after operation. 
Hydroxyproline levels are expressed as mean values + SD (n=12) of hydroxyproline concentration (mg/mg dry tissue) and hydroxyproline content (mg/mm tissue). 
A B
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Experiment 2: ileal anastomoses
Clinical course and survival: As in Experiment 1, the rats became severely ill and body weight decreased
during the three days of this experiment. No differences were observed in the course of body weight.
The survival rate was 100%.
Anastomotic strength and fascial wound strength: No differences between the groups were observed
in anastomotic bursting pressure, breaking strength, or fascial wound strength (Figure 6). Wound
hydroxyproline content or histology were not investigated.
DISCUSSION
The current study demonstrates that rtPA in a dosage sufficient to decrease the rate of intra-abdominal
abscesses in a peritonitis model does not affect the healing of colon and small bowel anastomoses nor
the abdominal fascial incision. Intra-abdominal abscesses are a well-recognized source of abdominal
sepsis, hence decreasing or preventing abscess formation should be an an important aim of treat-
ment(2;6). Fibrin deposition is an integral part of the host defense mechanism and a major factor in
the formation of abscesses (19), but it is also intrinsic to the normal wound healing sequence (20).
Figure 5. Anastomotic histology. 
Hematoxylin and eosin-stained sections of colonic anastomoses collected
on day 3 (a: controls and b: rtPA group) and day 7 (c: controls and d: rtPA
group). 
Figure 6. Wound breaking strength in experiment 2. 
Bursting pressure (BP, left y-axis) and breaking strength (BS, right y-axis)
for ileal anastomoses and fascial breaking strength at day 3 after operation.
Black bars represent rtPA group, white bars represent controls. Data are
depicted as mean + SEM (n=14). 
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Therefore intraperitoneal application of a fibrin-specific(12) plasminogen activator such as rtPA has
regained attention as an adjunct to the treatment of peritonitis to prevent residual or recurrent ab-
scesses (10;11;14;21). This line of research, however, has not as of yet led to intraperitoneal application
of fibrinolytic drugs in the clinical setting because clinicians fear impairment of wound healing and
the possibility of bleeding associated with intra-abdominal fibrinolysis.
A general conclusion regarding efficacy and safety of rtPA in the context of wound healing can not be
drawn from reported experimental studies, because these studies differ in design, dosage, and the
form of administration of tPA. Evans et al. showed in a non-infectious peritoneal ischemia model of 
adhesion formation that the concentration of rtPA in 0.9% NaCl needed to decrease formation of 
adhesions disrupts early wound healing of the abdominal fascia (13). These findings seem to be in con-
trast to those in the present study, where wound healing remained unaffected even after a 1.5-fold
greater intraperitoneal dose of rtPA (altogether 3.75 mg during 24 h). This apparent discrepancy may
be due to high levels of plasminogen activator inhibitors (PAI) which are supposedly present in our
model. Increased PAI levels present during peritonitis in both the abdominal compartment and plasma
result in less plasminogen activator activity (PAA) than might be expected on the basis of the dose
given(8;22-24). Houston et al. reported  a beneficial effect of rtPA on colonic anastomotic bursting
strength in a model of  perianastomotic infection(25). A single intraperitoneal dose of 0.04 mg rtPA has
been reported to be sufficient to treat a perianastomotic abscess but not to prevent abscesses in a
model of generalized peritonitis(26). Menzies and Ellis demonstrated that intraperitoneal application
of rtPA in rabbits in a non-infectious adhesion model did not adversely affect the colonic anastomotic
healing nor the strength of the abdominal fascial wound(27). RtPA was delivered in a gel formula,
which acts as a slow release vehicle, resulting in lesser intraperitoneal concentrations of the fibrino-
lytic agent. Altogether, the data now available, including those from the present, more comprehensive
study, suggest that exogenous tPA, in a dose which prevents abscess formation, does not impair wound
healing of intestinal anastomoses and the abdominal wall fascia.
Apart from the possible detrimental effects on wound repair, a second major concern of intraperito-
neal fibrinolytic therapy is the risk of local and systemic bleeding. As stated before, Van Goor et al. 
demonstrated that local as well as systemic PAA is decreased during peritonitis. As a consequence, the
risk of bleeding after administration of rtPA was considered to be low(22;28). In the current study only
one rat that died prematurely exhibited signs of bleeding, whereas all other animals did not, thereby
suggesting that bleeding manifestations after rtPA administration are unlikely. 
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The dose scheme used in the rtPA group was developed in prior studies in our laboratory(10;14). A five-
fold decrease in the original dose used by us (such as now used in the rtPA-low group) is still effective
in decreasing abscess formation and may be applied when prolonged treatment is desirable. Also, a 
decrease in abscess formation can still be achieved even if the first rtPA dose is delayed for 24 hours
(Buyne et al. unpublished data). This time frame was chosen (and applied in the current rtPA-del group),
because treatment of patients with an acute abdomen often starts some time after onset of perito-
nitis(29). Furthermore, it should also be emphasized that all rats in the present experiment received
antibiotics and developed abscesses, if rtPA treatment is omitted.
RtPA treatment does not weaken the bursting strength of anastomoses in either small or large bowel.
Whereas anastomosing the small bowel is well-accepted in patients with severe peritonitis, many 
surgeons are reluctant to perform primary, large bowel anastomosis. In the recent literature however,
a plea is made for constructing a primary anastomosis in treating perforated diverticulitis, a common
disorder that could benefit from rtPA treatment(30-32). This interest explains the focus of the present
study on healing of a colonic anastomosis, which we investigated comprehensively. The results were
confirmed for a small bowel anastomosis in a study of limited size. For the latter, the rtPA regimen
was chosen which we believe to constitute the highest risk: the highest dose investigated as admini-
stered immediately after operation. Also, analysis was limited to the 3rd postoperative day, where
wound strength is at its nadir and wounds are most vulnerable.   
The current animal model was developed to study different aspects of peritonitis and especially the
pathophysiology and treatment modalities of intra-abdominal abscesses(15). Our model, which repre-
sents many of the important features of secondary peritonitis, has proven to be reproducible with 
respect to the local cellular response, cytokine expression, and abscess formation(10;11;14) This model
has successfully been used to stepwise investigate the efficacy of rtPA in decreasing abscess formation
and has demonstrated that systemic antibiotic therapy alone has no added value in decreasing the rate
of abscess formation(11). In the current study, fascial and anastomotic healing, recognized as an 
important aspect of operative treatment of peritonitis, appears to be unaffected by fibrinolytic treat-
ment. The results of the sequential studies using this model justify clinical research on the safety and
efficacy of intraperitoneal application of rtPA.
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SUMMARY
Secondary peritonitis is a serious condition bearing significant morbidity and mortality. Improvements
have been made in the standard therapy for peritonitis, consisting of  surgical source control and de-
bridement, systemic antibiotic treatment and supportive (intensive) care. Yet, mortality and morbidity
have only marginally improved. In case of complications such as an intra-abdominal abscess, the
prognosis becomes even worse. These abscesses are well-known causes of recurrent or ongoing 
abdominal infection. The deposition of fibrin is a key step in abscess formation. Breaking down fibrin
or  preventing its formation is an obvious goal in order to combat abscesses.  
This thesis focuses upon the feasibility and efficacy of intraperitoneal administration of recombinant
tissue-type plasminogen activator (rtPA) to reduce abscess formation in a rat model of secondary
peritonitis.  
Chapter 1 describes the three major physiologic defense mechanisms of the abdominal cavity against
invasion of micro-organisms. I. Bacterial clearance via diaphragmatic stomata is achieved by cepa-
halad directed stream of peritoneal fluid. II. Upon peritoneal contamination local inflammatory cells,
i.e. macrophages and mesothelial cells, are activated and recruited. Cytokines and chemokines are 
expressed to further enhance the local inflammatory response. Permeability of local vessels increases
leading to formation of an  exudate containing chemokines and cytokines. III. Both intra-abdominal
fibrinolysis and coagulation are upregulated, the latter predominating in the early phase. As a 
consequence fibrin deposition occurs in order to contain or compartmentalize the focus of infection.
Next, factors are described that interfere with physiologic resolution of peritonitis. Fibrin adhesions
promote abscess formation and hamper bacterial clearance via the diaphragmatic stomata. Bacterial
synergy will further adversely influence the outcome of peritonitis.
The presence of adjuvant substances such as bile or blood impede the local inflammatory response. 
In the second section, the molecular properties of fibrin are described as well as its formation and 
degradation. In the abdominal cavity tissue factor is expressed predominantly by mesothelial cells as
a result of contamination or infection. Subsequently, the extrinsic pathway of coagulation is activated
via factor V, VII and X. Next, thrombin is activated and converts fibrinogen into fibrin. A fibrin mesh
is formed and subsequently factor XIIIa further stabilizes the fibrin mesh by cross-linking the fibrin
molecules.
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Physiologic break down of fibrin occurs by transformation of the pro-enzyme plasminogen into its
active from plasmin by plasminogen activators (Pas). Two types of PAs are recognized: urine-type PA
(u-PA) and tissue-type PA (tPA), only the latter being relevant in the abdominal cavity. Resolution of
fibrinolysis is achieved by counteraction of tPA by plasminogen activator inhibitor (PAI). Human 
mesothelial cells play a critical role in the process of both coagulation and fibrinolysis since procoa-
gulatory TF, fibrinolytic tPA as well as PAI are expressed by these cells.
Chaper 2 reports on the development of a model suitable to study several important features of 
secondary peritonitis, in particular the formation of abscesses and the local inflammatory response.
Fifty male Wistar rats were injected intraperitoneally with a mixture of sterile rat feces, increasing
doses of E. coli (104-108 cfu/ml) and a fixed dose of B. Fragilis (104 cfu/ml) thereby mimicking an 
intestinal perforation. Ten rats were injected with sterile rat feces only, and served as a control group.
In all rats, a laparotomy was performed after one hour and the peritoneal cavity was debrided. Blood
samples were taken after 6 and 24 hours, in order to perform bacterial culturing and to determine
plasma levels of IL-6 and TNFα. Abdominal fluid samples were collected after 24 and 72 hours. Local
peritoneal levels of the cytokines IL-1β, IL-10-, IL-6 and TNFα were determined and cell counts were
performed. The rats were killed after 5 days by CO2 asphyxation and the abdomen was inspected for
abscesses.
Mortality was 90% in the groups receiving the two highest doses of bacteria and 30% in the remaining
groups. In the latter groups all surviving rats but one showed intra-abdominal abscesses and bacte-
remia was encountered frequently, especially after 24 hours in the 105 cfu E. coli group. No systemic
levels of TNFα were detected and plasma IL-6 concentrations were elevated after 6 hours and signi-
ficantly lowered after 24 hours. Generally speaking, peritoneal cytokine levels were elevated in 
experimental groups as well as in controls after 24 hours and declined after 72 hours. The groups 
receiving the highest dose of bacteria had the highest levels of cytokines. The cellular response did
not differ between groups. The number of neutrophils was elevated at 24 hours and steadily declined
in time. Eosinophils increased and monocytes remained relatively stable throughout the experiment.
It was concluded that the present model for secondary peritonitis has provided satisfactory results
regarding abscess formation, survival and local inflammatory response. The model is suitable to study
the mechanisms involved in intra-abdominal abscess formation after surgical treatment of genera-
lized peritonitis.
In chapter 3 the model described in the preceding chapter was used to study the effect of intra-
abdominally applied rtPA on abscess formation. In previous experimental studies, rtPA was found to
be effective in reducing abscess formation in rodent models of peritonitis without any apparent 
increase in bleeding complications. However, in those studies intra-abdominal application of rtPA
was associated with considerable and significantly increased mortality, probably as a result of 
release of bacteria from the peritoneal cavity, with subsequent bacteriaemia, sepsis and/or an 
exaggarated local immune response. The present study was initiated to determine whether the 
effect of intra-abdominal application of rtPA can be optimized by  changing the method of application
and the dosage scheme. In addition, it was studied whether intraperitoneal rtPA therapy is associated
with an increased inflammatory response in the abdominal cavity, increased incidence and severity
of bacteremia or mortality.
Fifty-five animals were randomly divided into three groups of 14 and one group of 13 rats. Bacterial
peritonitis was induced as described in chapter 2 and surgical therapy was performed likewise. Three
experimental groups received intraperitoneal injections with 1.25 mg of rtPA at 1 h (rtPA1), 1 h and 6
h (rtPA2) and 1, 6 and 24 h (rtPA3) after inoculation, respectively. The animals in the fourth group 
(control) received sterile saline only at each time point. Blood samples for culture were taken at 6
and 24 hours after inoculation, peritoneal fluid samples for cytokines and cell counts were taken
after 24 hours. After 5 days the animals were killed by CO2 asphyxiation. The abdomen was inspected,
with particular attention to the number and location of abscesses.
RtPA treatment significantly reduced abscess formation. Animals in group rtPA3 had no abscesses in
contrast to 88% of the controls. In the rtPA1 and rtPA2 group, frequency of abscess formation was 58
and 33%, respectively. Mortality, course of body weight and bacteremia were not affected by rtPA and
neither were peritoneal cell counts and levels of TNF-α, IL-1β, IL-6 and IL-10. No bleeding complications
were observed.
The conclusion was that rtPA reduces intra-abdominal abscess formation after surgical treatment of
generalized peritonitis without increasing mortality or affecting the local inflammatory response.
In chapter 4 a comparison was made between two different fibrinolytic agents in a larger experiment.
Again, peritonitis was induced in 80 male Wistar rats as described earlier.
The animals were divided into four groups of twenty rats each. Two experimental groups were treated
by intra-abdominal administration of a fibrinolytic agent: one group was treated with three doses of
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1.25 mg rtPA at 1, 6 and 24 hours after inducing peritonitis, a second experimental group received
three doses of 725.000 IU of urokinase. One control group was treated with sterile saline only. A 
second control group served as a negative protein control and received 725.000 IU of streptokinase,
which does not affect the rat coagulatory system. Blood samples were taken for culture at 6 and 24
hours after inducing peritonitis and abdominal fluid samples were taken at 24, 72 and 120 hours for
cell counts and to determine levels of IL-6, IL-10 and TNFα. After 5 days the animals were sacrificed
and the abdomen inspected for the number and location of abscesses.
The data show that both rtPA and urokinase strongly (> 75%) and significantly (P < .05) reduced 
abscess formation without negative side effects. No bleeding complications were observed. Generally
speaking, fibrinolytic therapy resulted in less neutrophils and lymphocytes and more macrophages
and eosinophils in time but did not essentially alter the courses of IL-6 and IL-10 (decreasing in time)
or TNFα (increasing in time) levels.
It was concluded that both rtPA and urokinase effectively and safely reduce abscess formation in 
a rat model for treatment of secondary peritonitis.
In clinical practice, commencement of adequate therapy may vary due to the time elapsed between
onset of peritonitis and presentation of clinical symptoms or because of delay in establishing the 
diagnosis. In our experiments so far rtPA treatment has been restricted to the first 24 hours after 
inducing peritonitis. Therefore chapter 5 addresses the effect of delayed and prolonged treatment
with intraperitoneal rtPA. Anticipating the need to maximally reduce the treatment-related risk 
profile, the effect of lowering the dose was studied as well.
Bacterial peritonitis was induced in male Wistar rats as described before. Surgical debridement was
performed after 1 hour. Abdominal fluid samples were taken at  24 and 72 hours after inducing 
peritonitis for measurements of  Il-6, IL-10 and TNFα and cell counts. After 5 days rats were sacrificed
the abdomen was inspected for abscesses.
Two experiments were performed. In experiment I, four groups of animals (n=20 each) were treated
with rtPA. One group received 1.25 mg of rtPA at 1, 6 and 24 hours (rtPA), in another group rtPA treat-
ment was prolonged: 7 doses in 72 hours (rtPA prol). One group received three doses of rtPA  after 24
hour delay (rtPA 24) and another group after 48 hour delay (rtPA 48). There was one control group
(n=20) treated with saline at 1, 6 and 24 hours. In experiment II two groups (n=15 each) were treated
with three doses of rtPA of either 0.25 mg or 1.25 mg. 
Early administration of rtPA in both doses significantly reduced the number of rats with abscesses and
the abscess load per rat. Delayed treatment still significantly reduced abscess load but not the incidence
of abscesses. No adverse effects of intra-abdominal rtPA treatment were observed. No meaningful 
differences in local inflammatory response were found. RtPA was most effective when applied early
and for 72 hours. However, under those circumstances mortality increased significantly. No clear 
explanation for this observation was found.
These results corroborate the potential benefits of rtPA as an adjunct to the standard treatment of
peritonitis in the clinical setting. Safe rtPA dosages should be tested in a phase II study. In those cases,
where treatment for a longer period is needed, the effects of prolonged low dose rtPA treatment
should be investigated. 
Systemic antibiotic therapy is one of the important elements of the treatment of peritonitis. Until this
point antibiotic therapy was not administered in the consecutive studies in order to focus exclusively
on the effect of intra-abdominal fibrinolytic therapy.
Chapter 6 describes the effects of systemic antibiotics on intra-abdominal abscess formation and
survival, both in the absence and the presence of intraperitoneally applied rtPA.
Seventy-two animals were randomly divided into four equal groups. In all rats peritonitis was induced
as described earlier. The first (control) group received no further drug treatment, the second group
(rtPA) received three doses of 1.25 mg of rtPA intra-abdominally, the third group systemic antibiotics
(AB) and the fourth group antibiotics plus intra-abdominal rtPA (rtPA+AB) group. Antibiotic therapy
was given three days and consisted of 15 mg/kg Metronidazol and 15 mg/kg Ceftriaxone twice daily.
Blood samples for culture were drawn at 24 hours after inducing peritonitis. Abdominal fluid samples
were taken at 24, 72 and 120 hours for cell counts and to determine levels of IL-6, IL-10 and TNFα. 
As in the preceding experiments the animals were sacrificed after 5 days and the abdomen was 
inspected for number, size and location of abscesses.
Antibiotics did not significantly affect abscess formation but rtPA significantly reduced the number
of rats with abscesses and the abscess load per rat, both in absence and presence of antibiotic 
therapy. One rat died prematurely. No adverse side effects were observed and no meaningful diffe-
rences in the local inflammatory response were found.
The conclusion was that the administration of systemic antibiotics does not influence abscess 
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formation, while intra-abdominal application of rtPA consistently reduces abscess formation. In 
addition to systemic antibiotic therapy, rtPA is a valuable adjunct in the therapy of peritonitis.
As part of the surgical therapy for peritonitis, often an intestinal anastomosis needs to be constructed
or visceral organ repair will be needed otherwise. As shown in the preceding experiments, fibrinolytic
therapy reduces intra-abdominal abscesses. On the other hand, fibrin deposition is essential for and
intrinsic to early wound repair, providing a provisional scaffold for initial structural wound stability
and cell migration. It can be hypothesized that any interference with fibrin formation could lead to
wound healing disturbances, particularly so in anastomotic healing.
Chapter 7 addresses the possible effects of the intra-abdominal administration of rtPA on anastomotic
healing and healing of the fascial wound of the abdominal wall after surgical treatment for perito-
nitis in a rat model.
Peritonitis was induced and treated in 148 rats as described earlier. Two experiments were performed.
In experiment I, 1.25 mg of rtPA was given intraperitoneally at 1, 6 and 24 hours after inducing peri-
tonitis to one group. A second group was treated likewise but with 0.25 mg of rtPA. A third group 
received 1.25 mg of rtPA after 24 hour delay. The fourth group served as a control group and received
sterile saline at 1, 6 and 24 hours. Each group consisted of 30 rats. After surgical debridement, resec-
tion of 2 cm of the descending colon, 3 cm proximal to the peritoneal reflection was performed. 
Continuity was restored by constructing an end-to-end anastomosis with 8 single-layer, inverting, 
interrupted sutures. Within each group, half of the animals were killed at 3 and 7 days after operation,
respectively. In experiment II, ileal resection and anastomosis was performed immediately after 
debridement of the abdominal cavity and the animals were randomized into two groups (n=14 each),
a rtPA group and a control group. All rats were killed at the third postoperative day. In both experiments
abscesses were counted and bursting pressure, breaking strength and hydroxyproline content of
anastomoses and abdominal fascial wounds were determined.
Treatment with rtPA in both doses significantly reduced abscess formation. Colonic anastomoses as
well as fascial wounds increased in strength from day 3 to day 7. No significant difference between
groups were observed with respect to bursting pressure, breaking strength and hydroxyproline 
content for colonic as well as small bowel anastomoses. It was concluded that rtPA consistently 
reduces abscesses and does not affect the healing of intestinal anastomoses or the abdominal fascia.
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Introduction
Secondary peritonitis often also described as abdominal sepsis or abdominal infection, is caused by
loss of integrity of a hollow viscus and is a life threatening condition(1). Treatment is based on three
major principles. The first goal is to achieve source control by surgical intervention, i.e. resection, 
repair or isolation of the organ  involved and debridement. A second aim is timely commencement
of appropriate systemic antibiotic therapy. The third important measure is adequate high care 
support in order to restore and maintain tissue and organ perfusion and oxygenation(2;3). Despite
advances made with respect to surgical therapy, antibiotic treatment and intensive care supportive
treatment, mortality still is approximately 30%(4).
An intra-abdominal abscess is a known source of recurrent or ongoing abdominal sepsis(5;6). In those
patients where an intra-abdominal abscess develops during the course of treatment for secondary
peritonitis, mortality may increase up to 60%(7). Abscesses can be treated minimal invasively via per-
cutaneous drainage yielding a success rate of 80% in unilocular abscesses to 30% in more complicated
cases(8) However, if this option fails, surgical drainage must be performed. Repeat laparotomy entails
a hazard ratio of 2.5 for sepsis related complications and an overall mortality rate of 26%(9). These
numbers are even worse in case of urgent relaparotomy(10).
Considering the above, reduction of the formation of intra-abdominal abscesses is an obvious goal
in the treatment of  secondary peritonitis.
Fibrin
Fibrin is the major component of an abscess wall(11) and therefore reducing the fibrin content of
intra-abdominal abscesses was a main subject of this thesis. This can be achieved by two different
approaches. One can either interfere with intraperitoneal coagulation or enhance intra-abdominal
fibrinolysis. 
Anticoagulatory therapy in peritonitis
Attempts have been made to reduce intraperitoneal coagulation by heparin treatment. Bagree et al
reported 75% mortality after intraperitoneal adminstration of heparin(12). Controversely, others have
reported a reduction of abscesses together with an increased survival after intraperitoneal application
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of heparin in experimental peritonitis(13;14). It was shown in  several animal  models that subcuta-
neous application of heparin also reduced intra-abdominal abscesses and improved survival(13-19).
The working mechanism of heparin in peritonitis is unclear. A possible explanation is that heparin 
prevents the formation of fibrin and the subsequent entrapment of bacteria within fibrin, thereby
rendering the micro-organisms more susceptible to absorption from the peritoneal cavity via the
diaphragmatic lacunae and digestion by local peritoneal phagocytes(14). An important drawback 
on the use of heparin is its unpredictable anticoagulatory effect and the risk of bleeding(20;21). 
Another disadvantage might be the effect of heparin on wound healing in general. Performing an 
intestinal anastomosis or repairing an injured organ is often part of the surgical therapy. In cell culture
studies, heparin and growth factors are associated with rapid and effective endothelial cell repair
(22-24). There are however, no data on the effect of heparin on anastomotic healing.
Fibrinolytic therapy in peritonitis
Tissue-type plasminogen activator (tPA) has been applied in order to reduce abscess formation in ex-
perimental peritonitis. Rotstein et al reported a significant reduction of abscesses but also increased
mortality after intraperitoneal. administration of tPA. Mortality was reduced after administration of
systemic antibiotics(25;26). A similar abscess reducing affect of tPA  was reported by van Goor et al,
but no correlation between bacteremia and mortality was  found(27).  Activation of coagulation and
formation of fibrin deposits as a result of inflammation is considered instrumental in containing 
inflammatory activity to the site of injury or infection. Application of fibrinolytics potentially disturbs
this process. Bacteria caught in fibrin clots may be released much faster into the abdominal cavity
when intra-abdominal fibrinolytics are given, carrying the risk of bacteriaemia and sepsis. It is reaso-
nable to assume that mortality will increase as well, when no systemic antibiotics are given. This 
is supported by the fact that administration of systemic antibiotics almost completely prevents 
mortality(28;29).  We found no effect of r-tPA on the inflammatory response in the abdominal cavity,
whereas a systemic effect is very unlikely since r-tPA will be inactivated by PAI which is present in
high concentrations in the systemic circulation.   
Bleeding as a result of fibrinolytic therapy is unlikely to occur because of the fact that the systemic
plasminogen activator activity (PAA) after intraperitoneal administration of tPA has proven to be low
as a result of increased plasminogen activator inhibitor (PAI) levels(30).
The effect of tPA on wound healing, and anastomotic healing in particular, has been subject of 
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research. The results of studies on this subject are conflicting and the studies quite differ in doses of
tPA as well as in the way tPA was delivered(31-33). 
In the current literature on peritonitis, data are available on drugs which could be considered as 
alternatives to tPA. There is one case report on the succesful  use of urokinase for relapsing peritonitis
during the course of peritoneal dialysis(34). Studies on the application of polyanionic polysaccharides
yield equivocal results. Reijnen et al. have reported a significant reduction of abscesses after intra-
peritoneal adminstration of hyaluronic acid (HA) and carboxymethyl cellulose (CMC)(24;35;36) ,while
Sikkink et al. found no reduction in abscess formation(37). Bae et al. have shown that polysaccharides
isolated from  Phellinus mushrooms also significantly reduce abscesses(38;39). Several experimental
studies indicated that polysaccharides do not affect anastomotic strength(40-44), but in one study
CMC was associated with an increased rate of perianastomotic abscess(45). In a randomized clinical
trial regarding to the effect of polysaccharides on anastomotic healing, it was found that CMC 
adversely affects the sequelae of anastomotic leakage(46). 
The ultimate goal of any experimental research would be to employ the results in clinical practice.
In this dissertation several clinically relevant issues have been addressed. The feasibility and efficacy
of intra-abdominal administration of rtpA in order to reduce abscess formation was demonstrated.
RtPA repeatedly and consistently reduced the number of abscesses as well as the abscess load after
surgical treatment for peritonitis. Intra-abdominal fibrinolytic therapy does not interfere with the
local inflammatory response and does not increase the risk of bleeding. The incidence and severity
of bacteremia was not affected by rtPA. Systemic antibiotic therapy has no additional value with 
respect to the reduction  of intra-abdominal abscess formation. Furthermore anastomotic healing as
well as healing of the abdominal fascial wound were not affected. 
Based on these findings clinical research on the utilisation of intra-abdominal recombinant tissue-type
plasminogen activator is warranted.
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Secundaire peritonitis is een ernstige ziekte die gepaard gaat met aanzienlijke morbiditeit en 
mortaliteit. Er is vooruitgang geboekt in de standaardbehandeling van peritonitis, die bestaat uit
chirurgisch debridement, dan wel isoleren van de bron van infectie, het toedienen van systemische
antibiotica en recuscitatie en intensive care behandeling. Desondanks zijn mortaliteit en morbiditeit
slechts weinig verbeterd. Wanneer er een complicatie optreedt gedurende de behandeling, zoals 
bijvoorbeeld een intra-abdominaal abces, wordt de prognose slechter. Deze abcessen zijn een be-
kende oorzaak van recidiverende of voortschrijdende abdominale infectie. 
De vorming van fibrine is een belangrijke stap in het ontstaan van een abces. Het afbreken van fibrine
of het voorkomen van fibrinevorming is derhalve een voor de hand liggend doel om de ontwikkeling
van abcessen tegen te gaan. 
Dit proefschrift richt zich op de haalbaarheid en efficiëntie van intraperitoneale toediening van 
recombinant tissue-type plasminogene activator (rtPA) om abcesvorming in een rattenmodel voor 
secundaire peritonitis te voorkomen.
Hoofstuk 1 beschrijft de drie belangrijkste fysiologische afweermechanismen van de buikholte tegen
invadering door micro-organismen: I. Klaring van bacteriën via stomata in het diafragma als gevolg
van de craniaalwaarts gerichte circulatie van peritoneaal vocht. II. Na contaminatie van het peritoneum
worden locale ontstekingscellen, zoals macrofagen en mesotheelcellen, gerekruteerd en geactiveerd.
Cytokines en chemokines komen tot expressie en versterken de locale inflammatoire respons. De
doorlaatbaarheid van de locale vaten neemt toe, wat leidt tot een fibrinogeenrijk exsudaat dat 
chemokines en cytokines bevat. III. Zowel intra-abdominale fibrinolyse als coagulatie zijn geactiveerd,
waarbij de laatste de overhand heeft in de vroege fase. Als gevolg hiervan zal zich fibrine vormen,
met als doel om het focus van infectie af te grenzen. 
Hierna worden in dit hoofdstuk factoren beschreven die interfereren met de fysiologische reactie
van de buikholte op de peritonitis. Fibrineuze adhesies bevorderen de vorming van abcessen en ver-
hinderen de bacteriële klaring via de stomata van het diafragma. Bacteriële synergie zal de uitkomst
van peritonitis nog verder negatief beïnvloeden. De aanwezigheid van adjuvante stoffen zoals gal of
bloed verstoren de locale inflammatoire respons. 
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In het tweede deel van hoofdstuk 1 worden de vorming en afbraak, alsmede de moleculaire 
eigenschappen van fibrine beschreven. Als gevolg van contaminatie of infectie wordt in de buikholte
tissue factor (TF) tot expressie gebracht. Dit gebeurt voornamelijk door de mesotheelcellen. Vervol-
gens wordt de extrinsieke stollingsroute geactiveerd via respectievelijk factor V,VII en X. Hierna wordt
thrombine geactiveerd en hierdoor wordt fibrinogeen omgezet in fibrine. Een fibrineus netwerk
wordt gevormd en vervolgens verder gestabiliseerd door factor XIIIa die de vorming van dwarsver-
bindingen tussen de fibrine moleculen induceert. De fysiologische afbraak van fibrine gebeurt door
plasmine, dat ontstaat na omzetting van het pro-enzym plasminogeen in zijn actieve vorm, door
plasminogeen activatoren (PAs). Er zijn twee type PAs bekend: urine-type PA (u-PA) en tissue-type PA
(tPA), waarbij de laatste relevant is in de buikholte. Fysiologisch wordt de fibrinolyse beëindigd door
het tegengaan van de werking van tPA door plasminogeen activator inhibitor (PAI). De mesotheel-
cellen spelen een sleutelrol in zowel stolling als fibrinolyse van de buikholte, omdat het procoagula-
toire TF, het fibrinolytisch werkende tPA, maar ook PAI door deze cellen tot expressie worden gebracht.
Hoofdstuk 2 beschrijft de ontwikkeling van een model wat geschikt is om verschillende kenmerken
van secundaire peritonitis te bestuderen, in het bijzonder de vorming van abcessen en de locale 
inflammatoire respons. Vijftig mannelijke Wistar ratten werden intraperitoneaal geïnjecteerd met een
mengsel van gesteriliseerde rattenfeces, oplopende doses E. Coli (104-108 cfu/ml) en een vaste dosis
B. Fragilis (104 cfu/ml). Op deze wijze werd een intestinale perforatie nagebootst. Tien ratten werden
geïnjecteerd met alleen steriele feces en dienden als controlegroep. In alle ratten werd na één uur een
laparotomie uitgevoerd, waarbij de peritoneaalholte werd ontdaan van avitaal en geïnfecteerd weef-
sel. Na 6 en 24 uur werden bloedmonsters genomen voor bacteriologische kweken en om plasma-
spiegels van IL-6 en TNF-α te bepalen. Monsters van buikvocht werden genomen op 24 en 72 uur na
inductie van peritonitis. Hierin werden spiegels van IL1-β, IL-10, IL-6 en TNF-α bepaald en celtellingen
uitgevoerd. De ratten werden opgeofferd na 5 dagen door CO2-asphyxie en de buikholte werd 
geïnspecteerd op de aanwezigheid van abcessen. 
De sterfte bedroegt 90% in de groepen die de hoogste dosis bacteriën toegediend kregen en 30% in
de overige groepen. In de laatste groepen werden in alle overlevende ratten intra-abdominale 
abcessen aangetroffen en was er sprake van een bacteriëmie, met name na 24 uur in de 105 cfu E. coli
groep. In het bloed was geen TNF-αmeetbaar; plasmaspiegels van IL-6 waren verhoogd na 6 uur en
daalden significant na 24 uur.
In het algemeen gesteld waren de cytokinespiegels in het buikvocht verhoogd, in zowel de experi-
mentele groepen als in de controles na 24 uur. Deze spiegels namen af na 72 uur. De groepen die de
hoogste dosis bacteriën toegediend hadden gekregen, vertoonden ook de hoogste cytokineconcen-
traties. De cellulaire reactie verschilde niet significant tussen de groepen. Het aantal neutrofielen
was verhoogd na 24 uur en daalde gestaag gedurende het experiment. Het aantal eosinofielen steeg
en het monocytengetal bleef relatief stabiel. 
De conclusie was dat het huidige model voor secundaire peritonitis voldoet aan de eisen voor wat 
betreft de vorming van abcessen, de overleving en de locale cytokinerespons. Het model is geschikt
is om mechanismen te bestuderen met betrekking tot de vorming van intra-abdominale abcessen na 
chirurgische behandeling van gegeneraliseerde peritonitis.
In hoofdstuk 3 wordt beschreven hoe het model zoals genoemd in het vorige hoofdstuk is toegepast
om het effect te bestuderen van intra-abdominaal toegediende recombinant tPA (rtPA) op de vorming
van abcessen. In eerdere experimentele studies is bewezen dat rtPA effectief is in het reduceren van
abcessen in knaagdiermodellen voor peritonitis zonder dat er een toename van bloedingscomplicaties
optreedt. Echter in deze studies was intra-abdominale behandeling met rtPA geassocieerd met een
aanzienlijke en significant verhoogde mortaliteit, waarschijnlijk als gevolg van een verhoogde klaring
van bacteriën uit de buikholte met als gevolg een bacteriëmie en sepsis, dan wel als gevolg van  een
“overdreven” locale immuunrespons. De huidige studie werd uitgevoerd om te bepalen of de intra-
abdominale toediening van rtPA kan worden geoptimaliseerd door de manier van toediening en het
doseringsschema aan te passen. Daarnaast werd onderzocht of het intraperitoneaal toedienen van
rtPA geassocieerd is met een verhoogde inflammatoire respons in de buikholte, een verhoogde 
incidentie en ernst van bacteriëmie of toegenomen mortaliteit.
Vijfenvijftig ratten werden steeksproefsgewijs verdeeld in 3 groepen van 14 en 1 groep van 13. Bacteriële
peritonitis werd geïnduceerd, gevolgd door chirurgische behandeling, zoals beschreven in hoofdstuk
2. Drie experimentele groepen ontvingen intraperitoneaal 1,25 mg rtPA 1 uur (rtPA1), 1 uur en 6 uur
(rtPA2) of 1,6 en 24 uur (rtPA3) na inoculatie. De dieren in de vierde groep werden behandeld met een
steriele zoutoplossing op alle genoemde tijdstippen. Er werden bloedmonsters afgenomen voor bac-
teriële kweken op 6 en 24 uur na inoculatie. Buikvochtmonsters werden afgenomen na 24 uur om
spiegels van cytokines te bepalen en celtellingen uit te voeren. Na 5 dagen werden de ratten gedood
door CO2-asphyxie. De buik werd geïnspecteerd op de aanwezigheid en de locatie van abcessen. 
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Behandeling met rtPA leidde tot een significante reductie van abcesvorming. Ratten die 3 doses rtPA
hadden ontvangen, vertoonden géén abcessen in tegenstelling tot 88% van de controles, en 58% en
33% van de ratten die respectievelijk 1 of 2 doses rtPA hadden ontvangen. 
Sterfte, het verloop van het lichaamsgewicht en de incidentie van bacteriëmie werden niet beïnvloed
door toediening van rtPA, evenmin als de celtellingen en de spiegels van TNF-α, IL-1β, IL-6 en IL-10. Er
werden geen bloedingscomplicaties gezien. 
De conclusie luidde dat rtPA de vorming van intra-abdominale abcessen vermindert zonder toename
van mortaliteit en zonder de locale inflammatoire reactie te beïnvloeden.
Hoofdstuk 4 beschrijft een groter experiment waarin een vergelijking werd gemaakt tussen twee 
fibrinolytica die qua werkingsmechanisme verschillen. Opnieuw werd een peritonitis geïnduceerd in
80 mannelijke Wistar ratten, zoals eerder beschreven. De dieren werden verdeeld in 4 groepen van
20 ratten. Twee groepen werden behandeld met een intra-abdominaal fibrinolyticum. Een groep 
ontving 3 doses van 1.25 mg rtPA op 1, 6 en 24 uur na inductie van peritonitis, een tweede groep werd
behandeld met 3 doses van 725.000 IU urokinase. Een controlegroep werd behandeld met een 
steriele zoutoplossing en een tweede controlegroep diende als negatieve eiwitcontrole en werd 
behandeld met 3 x 725.000 IU streptokinase. Van deze stof is bekend dat zij het stollingssysteem van
de rat niet beïnvloedt. Er werden bloedmonsters genomen voor bacteriologische kweken op 6 en 24
uur na inductie van peritonitis en buikvochtmonsters op 24, 72 en 120 uren voor celtellingen en om
spiegels van IL-6, IL-10 en TNF-α te bepalen. Na 5 dagen werden de dieren opgeofferd en de buik-
holte geïnspecteerd op de aanwezigheid en locatie van abcessen. 
RtPA en urokinase bleken beiden duidelijk significant het aantal abcessen te reduceren zonder dat er
negatieve bijwerkingen waren. Er werden geen bloedingscomplicaties gezien. 
In het algemeen gesteld leidde fibrinolytische therapie tot een verminderd aantal intra-abdominale
neutrofielen en lymfocyten en tot een verhoging van het aantal macrofagen en eosinofielen gedurende
het experiment. Echter het beloop van de  IL-6 en IL-10 (afname gedurende het experiment) of TNF-α
(toename gedurende het experiment) spiegels in het buikvocht werd niet beïnvloed door rtPA.
Als conclusie werd gesteld dat in een rattenmodel voor de behandeling van secundaire peritonitis met
zowel rtPA als urokinase effectief en veilig abcesvorming kon worden tegengegaan.
In de klinische praktijk zal de aanvang van adequate therapie variëren als gevolg van de tijd die 
verloopt tussen de aanvang van ziekte en presentatie van klinische symptomen of als gevolg van het
niet direct stellen van de juiste diagnose. Hierbij komt dat tot op heden de (experimentele) behan-
deling met rtPA alleen gedurende de eerste 24 uur na inductie van peritonitis is toegepast.
Om deze reden beschrijft hoofdstuk 5 het effect van uitgestelde en verlengde behandeling van het
intraperitoneaal toegediende rtPA. Vooruitkijkend naar een eventuele noodzaak om het risico van
deze behandeling nog verder te reduceren werd ook onderzocht wat het effect was van een dosis-
verlaging.
Bacteriële peritonitis werd geïnduceerd in mannelijke Wistar ratten zoals eerder beschreven. Chirur-
gische interventie werd na één uur uitgevoerd. Er werden buikvochtmonsters genomen op 24 en 72
uur na inductie van peritonitis om IL-6, IL-10 en TNF-α spiegels te meten en celtellingen uit te 
voeren. Na vijf dagen werd de buikholte geïnspecteerd op de aanwezigheid van abcessen.
Er werden twee experimenten uitgevoerd. In experiment I werden vier groepen ratten behandeld
met rtPA. Een groep werd behandeld met 1,25 mg rtPA na 1, 6 en 24 uur (rtPA), een andere groep ont-
ving een verlengde behandeling: 7 doses werden toegediend gedurende 72 uur (rtPA prol). Een groep
ontving 3 doses van rtPA na een uitstel van 24 uur (rtPA 24) en een andere groep na een uitstel van
48 uur (rtPA 48). Een controlegroep werd behandeld met een steriele zoutoplossing op 1, 6 en 24 uur.
In het tweede experiment werden twee groepen behandeld met respectievelijk 3 x 0,25 mg of 1,25 mg
rtPA (gedurende de eerste 24 uur).
Vroege toediening van rtPA in beide doses leidde tot een significante reductie van het aantal ratten
met abcessen alsmede het aantal abcessen per rat. Uitgestelde behandeling leidde nog steeds tot een
significante daling van het aantal abcessen per rat, maar niet tot daling van de incidentie van 
abcessen. Er werden geen negatieve bijwerkingen van de intra-abdominale rtPA behandeling gezien.
Er waren geen verschillen van betekenis voor wat betreft de locale inflammatoire respons. RtPA was
het meeste effectief bij continuering van de toediening gedurende 72 uur. Echter, er werd een 
verhoogde mortaliteit waargenomen na verlengde behandeling met de standaard dosis van 1,25 mg.
Hiervoor was geen duidelijke verklaring. 
Deze resultaten bevestigden de  potentiële waarde van rtPA als toevoeging aan de standaardbe-
handeling van peritonitis in de klinische situatie. De veiligheid van doseringsschema’s dient te worden
getest in een fase II klinisch onderzoek. Het effect van een verlengde behandeling met lagere doses
rtPA dient onderzocht te worden in die gevallen waarin langdurige behandeling geïndiceerd is.
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Het toedienen van systemische antibiotica is een belangrijk element van de behandeling van peri-
tonitis. Tot nog toe was er nog geen antibiotische therapie toegepast in de hiervoor beschreven stu-
dies studies. Dit om specifiek het effect van het intra-abdominaal toedienen van fibrinolytica te
bestuderen.
Hoofdstuk 6 beschrijft het effect van de systemische toediening van antibiotica op intra-abdominale
abcesvorming, zowel met als zonder intraperitoneale toediening van rtPA. 
Tweeënzeventig ratten werden door loting verdeeld in 4 gelijke groepen. In alle ratten werd de peri-
tonitis opgewekt als eerder beschreven. De eerste (controle) groep kreeg geen verdere medicamenteuze
behandeling, de tweede groep (rtPA) werd behandeld met 1,25 mg rtPA intra-abdominaal, de derde
groep werd behandeld met systemische antibiotica (AB) en de vierde groep met systemische antibio-
tica en intra-abdominaal toegediende rtPA (rtPA + AB groep). Antibiotische therapie werd gedurende
3 dagen toegediend en bestond uit 15 mg/hg Metronidazol en 15 mg/kg Ceftriaxon, tweemaal daags.
Er werden bloedmonsters afgenomen voor bacteriologische kweken op 24 uur na inductie van 
peritonitis. Buikvochtmonsters werden afgenomen op 24, 72 en 120 uur en werden gebruikt voor 
celtellingen en om spiegels van IL-6, IL-10, TNF-α te bepalen. Zoals in de eerdere experimenten werden
de dieren opgeofferd na 5 dagen en werd de buikholte geïnspecteerd op de aanwezigheid en de 
locatie van abcessen. 
Antibiotica op zich hadden geen invloed op de vorming van abcessen, maar intra-abdominale toe-
diening van rtPA leidde tot een significante reductie van het aantal ratten met abcessen alsook de
abceslast (als maat voor de totale hoeveelheid abcessen) per rat. Dit bleek ook het geval te zijn in de
ratten die naast rtPA eveneens behandeld werden met systemische antibioticatherapie.
Eén rat overleed voor het einde van het experiment. Er werden geen negatieve neveneffecten 
gevonden en er waren geen verschillen van betekenis voor wat betreft de locale inflammatoire respons.
De conclusie luidde dat intra-abdominale toediening van rtPA leidt tot een consistente afname van
abcessen. De systemisch toediening van antibiotica beïnvloedt abcesvorming niet. Naast antibiotica
is rtPA is een waardevolle aanvulling bij de behandeling van peritonitis.
Vaak wordt als deel van de chirurgische behandeling van peritonitis een intestinale anastomose 
geconstrueerd of herstel van een visceraal orgaan uitgevoerd. Zoals aangetoond in de eerder 
uitgevoerde experimenten leidt fibrinolytische therapie tot afname van het aantal intra-abdominale
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abcessen. Van de andere kant is fibrinevorming een essentieel proces tijdens vroege wondgenezing
welke moet leiden tot een provisorische matrix voor de initiële wondstabiliteit en celmigratie. 
Hypothetisch zou reductie van fibrinevorming dus kunnen leiden tot verstoringen van de wond-
genezing, in dit geval in het bijzonder tot verstoring van de genezing van een anastomose.
In hoofdstuk 7 worden de mogelijke effecten van de intra-abdominale toediening van rtPA op naad-
genezing en genezing van de fascie van de buikwand beschreven na chirurgische behandeling voor
peritonitis in een rattenmodel.
Peritonitis werd geïnduceerd en behandeld in 148 ratten zoals hierboven beschreven. Er werden twee
experimenten uitgevoerd. In experiment I  kreeg een groep op 1, 6 en 24 uur na inductie van peritonitis
1,25 mg rtPA intraperitoneaal toegediend. Een tweede groep werd op dezelfde wijze behandeld, 
echter met een dosis van 0,25 mg. Een derde groep werd behandeld met driemaal 1,25 mg rtPA 
beginnend na 24 uur. De vierde groep was de controlegroep en werd behandeld met een steriele 
zoutoplossing op 1, 6 en 24 uur. Elke groep bestond uit 30 ratten. In elke groep werd, na chirurgisch
debridement 1 uur na injectie van het bacteriële inocilum, 2 cm van het colon descendens gereseceerd
op 3 cm proximaal van de peritoneale omslagplooi. Continuïteit werd hersteld door middel van een
end-to-end anastomose met 8 volledige wanddikte omvattende, inverterende, staande hechtingen.
In elke groep werd de helft van de dieren gedood op de derde dag en de andere helft op de zevende
dag na de operatie. In experiment II werd een ileumresectie en anastomose uitgevoerd direct na 
chirurgisch debridement van de buikholte. De dieren werden verdeeld in twee groepen (n=14), een
rtPA groep en een controlegroep. Alle ratten werden op de derde postoperatieve dag gedood. In beide
experimenten werden de abcessen geteld, barstdruk, breeksterkte en het hydroxyprolinegehalte van
anastomoses en van de abdominale fascie gemeten. 
Behandeling met rtPA in beide doses leidde tot een significante reductie van abcessen. De sterkte van
zowel colonnaden als de wonden van de buikwandfascie nam significant toe van dag 3 tot dag 7. Er
waren geen significante verschillen tussen de groepen met betrekking tot barstdruk, breeksterkte en
hydroxyprolinegehalte. Dit gold zowel voor de colon- als voor de dunne darm anastomoses. 
De conclusie luidde dat toediening van rtPA leidt tot een consistente reductie van abcessen en geen
invloed heeft op de genezing van intestinale anastomoses of de buikwandfascie.
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Geachte promotor, beste Rob,
Ooit heb je mij uit het hoge noorden weggelokt om in Nijmegen te komen werken. De aanleiding lag
ongetwijfeld in een gedeelde belangstelling voor peritonitis en andere chirurgische infecties. Je bleek
niet alleen een enthousiaste onderzoeker, maar ook een uitstekend chirurg en gewaardeerde 
collega. Je hebt jouw rol als promotor met verve vervuld. Uit een soms niet te stuiten stroom van
ideeën en gedachten is uiteindelijk de definitieve vorm van dit proefschrift ontstaan. Dank voor al 
hetgeen jij bij hebt gedragen.
Geachte copromotor, beste Harry,
Ooit probeerde jij mij te interesseren voor het schrijven van een proefschrift. De letterlijke woorden
waren: “Je kunt hier zo promoveren. Ik heb nog genoeg op de plank liggen. Je hoeft het alleen maar
op te schrijven.” Gelukkig was de werkelijkheid anders. Volgens mij ligt jouw plank voller dan ooit en
ben ik niet diegene die hem leger zal maken. Mede door jouw innovatieve ideeën, jouw creatief denken
en nooit aflatende kritische blik op opzet, uitvoering en uitwerking is dit proefschrift geworden tot
wat het is. Zeer veel dank voor jouw bijdrage aan dit proefschrift.
Geachte copromotor, beste Thijs,
Gaande de totstandkoming van dit proefschrift werd mij al vlot een aantal zaken duidelijk. Als jij “ja”
tegen een klus zegt, dan maak jij die ”ja” volledig waar. Je bent een zeer kritische en toegewijde be-
geleider die uitstekend kan schrijven, corrigeren en redigeren. Ik heb bijzonder veel van je geleerd en
heb je leren waarderen als een uiterst verstandig, consequent, betrouwbaar en aangenaam mens. Op
gevaar van dat je mij eraan gaat houden: ik zou het zo nog een keer doen (are you kidding me!!!).
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Professor Verweij, beste Paul,
Vanaf het begin heb jij je medewerking verleend aan de uitvoering van de vele medisch microbiolo-
gische handelingen. Daarnaast heb jij ook jouw bijdrage geleverd aan het corrigeren en redigeren van
de manuscripten. Dank hiervoor.
Ben de Man en Roger Lomme,
Ik weet dat jullie nooit staan te springen om in de belangstelling te staan. De samenwerking om de
feitelijke handelingen te plegen (ik denk aan de vele experimenten die wij deden) is verder gegaan
dan een uitsluitend beroepsmatige. Jullie zijn fantastische researchlaboranten, aangename en 
bescheiden mensen die met de nodige humor alle klussen, hoe groot dan ook, zeer naar tevredenheid
hebben afgerond. Met jullie een experiment doen was voor mij altijd een zeer aangename onder-
breking van de soms drukke klinische taken. Ik ben jullie zeer veel dank verschuldigd.
Hein van der Lee,
Jij hebt vele microbiologische kweken voor ons moeten inzetten op af en toe ongemakkelijke tijden.
De bacteriestammen die jij ons aanleverde hebben altijd voldaan en je hebt ons met tips en trics 
bijgestaan. Ik dank je voor jouw bijdrage.
Medewerkers Centraal Dierenlaboratorium,
Mijn dank gaat uit naar jullie allemaal. Er is door deze groep experts een substantiële bijdrage gele-
verd aan de praktische uitvoering van de vele dierexperimenten. Hoewel ik niemand te kort wil doen,
noem ik toch in het bijzonder Geert Poelen. 
De manuscriptcommissie,
Ik dank de manuscriptcommissie voor het zeer kritisch lezen van het manuscript.
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Collega stafchirurgen, fellows, chivo’s, arts-assistenten en secretariaat van de afdeling Heelkunde,
Bewust of onbewust dragen jullie er allemaal aan bij dat ik nog steeds elke dag fluitend op mijn fiets
spring op weg naar het ziekenhuis. Dank hiervoor.
Marrit Siebers,
Naast een meer dan full time baan als secretaresse voor een aantal collega’s zag jij nog kans om mij
te helpen met allerlei hand-en-spandiensten rondom dit proefschrift. Klein maar dapper, zou ik zeggen.
Zeer veel dank.
Dr O.H Buyne, beste Otmar Sr.
Pa, ik dank je voor  het altijd tonen van belangstelling voor mijn wetenschappelijke vorderingen. Je
hebt mij altijd gestimuleerd om mijzelf verder te ontwikkelen en vond dat een proefschrift daarbij
hoorde.  Verder ben je iemand die nooit is vergeten waar het echt om gaat in het leven. Jouw credo
zou kunnen zijn: ontwikkel jezelf maar zet je ook in voor een ander. Verloochen je afkomst nooit  en
vergeet vooral niet dat het leven er is om van te genieten. 
Voor al mijn vrienden en familie.
Jullie zijn een rijk bezit. Of we elkaar nou veel of weinig zien, ik ben altijd welkom en het contact is
altijd hartelijk. Jullie hebben geen idee hoe ontzettend belangrijk het is dat jullie er zijn om mij af en
toe uit de wondere wereld der geneeskunde te trekken en met beide benen op de grond zetten. 
So so lobi.
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De paranimfen, 
Beste Peter, wij kennen elkaar relatief kort, maar al snel werd mij duidelijk dat je als gewaardeerde
collega, als prettig gestoord mens maar ook als on-the-spot organisator vele talenten bezit. Na jouw
optreden als presentator van een Karaoke show was ik geheel overtuigd. 
Roel,  ik kan mij niet herinneren wanneer ik jou voor het laatst bij je ware naam genoemd heb. Wat
voor mij niets anders betekent dan dat onze vriendschap, net zoals de enige roepnaam die echt bij
jou past, zou oud voelt als de weg naar Rome. En dat moet maar heel lang zo blijven. 
Zeer veel dank dat jullie mij hebben willen bijstaan op deze bijzondere dag.
Mijn dames: Loïs, Nicchelle en Caïsa.
Jullie hebben werkelijk niets aan dit proefschrift bijgedragen anders dan mij er regelmatig aan her-
inneren dat het “nog steeds” niet af  was en dat je nou toch eindelijk die nieuwe kleren wilde aan-
schaffen voor het feest. Toch was ook dat een stok achter de deur. Het is nu eindelijk af en dat is maar
goed ook. Dat ik het langzamerhand moet afleggen tegen de snelheid waarmee jullie een gemiddeld
modern electronisch apparaat bedienen, is namelijk op zich al erg genoeg. 
Voor mijn lief, Anita Samsom.
Voor jou kan ik het kort houden en meer hebben wij ook niet nodig. Dit proefschrift zou nooit zijn 
geweest wat het nu is, als jij er niet was geweest. Net zoals ik niet half had kunnen zijn wat, waar en
wie ik nu ben, zonder jouw onvoorwaardelijke steun, vertrouwen en liefde. 
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CURRICULUM VITAE
Otmar Buyne werd in 1965 geboren in Utrecht.
Na enige jaren heen en weer te hebben gereisd tussen Curaçao, Suriname en Nederland deed hij in
1982 eindexamen op het Maartenscollege in Haren (Groningen).
Na een jaar Farmacie werd hij ingeloot voor de studie Geneeskunde in Groningen. Hij behaalde zijn
doctoraal examen in 1991. Tijdens het volgen van de co-schappen in het St Elisabeth Hospital in 
Willemstad, Curaçao, werd de belangstelling voor de heelkunde geboren. Na terugkeer in Nederland
volgde hij een keuze co-schap chirurgie in het Medisch Centrum Leeuwarden, toen nog met dr. P. de
Vogel als opleider. 
Na een periode van drie jaar, waarin hij keuringsarts, arts-assistent Intensive care gecombineerd met
heelkunde en ook arts op het Brandwondencentrum Groningen was, werd hij aangenomen voor de
opleiding heelkunde.
Het perifere deel van de opleiding werd gevolgd in het Martini Ziekenhuis Groningen met als opleider
dr. L. Vos en later dr. H. Oeseburg. De laatste drie jaren van de opleiding heelkunde werden onder 
leiding van prof. R van Schilfgaarde gevolgd in het Academisch ziekenhuis Groningen nu UMCG 
geheten. 
Na een korte periode van waarneming in het Wilhelmina Ziekenhuis te Assen heeft hij bijna een jaar
als tijdelijk staflid Traumatologie in het UMCG gewerkt onder leiding van prof HJ. ten Duis. Hierna
werd hij aangesteld als fellow gastrointestinale chirurgie en traumatologie in het Universitair 
Medisch Centrum Nijmegen St Radboud, waar hij uiteindelijk toe is getreden tot de staf Gastroin-
testinale chirurgie en tot op heden werkzaam is.
Hij woont in Nijmegen samen met Anita Samsom en hun drie dochters Loïs, Nicchelle en Caïsa.
152 Curriculum vitae

